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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Introduction
Chronic fatigue syndrome (CFS) is still an enigmatic disorder. It is regarded as a 
complex disorder with tremendous impact on the lives of patients, their families 
and society in general. Full recovery without treatment is rare, with only 5% of the 
patients showing spontaneous recovery. The mean age of onset is between 29 
and 35 years1. Women are more at risk than men and many patients have 
experienced a period in which they were bound to their homes. In 2005 the Dutch 
Health Council estimated a prevalence of 30,000 to 40,000 CFS patients in The 
Netherlands, based on prevalence studies in Dutch general practices2. A more 
recent study performed in the general population suggests there are probably 
about 80,000 CFS patients in The Netherlands3. 
 The Expert Centre for Chronic Fatigue (ECCF) of the Radboud University 
Nijmegen Medical Centre is a multidisciplinary collaborative centre focussing on 
the assessment and management of patients with CFS. Since 1989, internists, 
virologists, neurologists, neuroscientists, psychiatrists and psychologists have 
been involved in CFS research in Nijmegen. During the years, the research has 
extended to chronic fatigue in several other conditions including rheumatoid 
arthritis, traumatic brain injury, myotonic dystrophy and cancer4,5,6,7. 
Definition Chronic Fatigue Syndrome
Holmes et al. developed the first CFS working case definition8 in 1988. In 1994 
and in 2003, the Expert Centre contributed to the development of international 
guidelines for the clinical evaluation and research of CFS, resulting in the 1994 
case definition which is currently considered to be the standard (see panel)9,10. 
The 1994 case definition was primarily developed for research purposes, in which 
case specificity is important. In this thesis, the 1994 CDC criteria were used in all 
studies presented. 
There is much debate among researchers and practitioners about the patho-
physiology and definition of CFS11,12. Although the case definitions differ, all definitions 
identify severely fatigued CFS patients from healthy control subjects of the same 
age and sex. 
 There are no pathognomonic signs or diagnostic test for CFS13. CFS is diagnosed 
by the presence of clinical symptoms, disability and by exclusion of certain psychiatric 
disorders and medical conditions explaining fatigue. 
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CFS and psychiatric disorders
Psychiatric disorders play an important and complex role in chronic fatigue syndrome. 
 First, as described previously, certain psychiatric diagnoses are exclusion 
criteria for CFS. The recommendations formulated by Fukuda et al. define current 
or past psychiatric disorders such as melancholic or psychotic depression, bipolar 
disorder, delusional disorder  schizophrenia, anorexia nervosa or bulimia nervosa 
as exclusion criteria for CFS. It is difficult to interpret CFS symptoms in these 
psychiatric disorders, and care and treatment should focus on the psychiatric 
disorder. 
In 2003, recommendations for a better application of the 1994 case definition 
were made and psychiatric exclusion criteria were further elaborated. If a major 
depressive disorder with psychotic or melancholic features, anorexia nervosa or 
Panel:  1994 case definition for CFS from US Centers for Disease Control  
and Prevention
Characterised by persistent of relapsing unexplained chronic fatigue
•	 Fatigue lasts for at least 6 months
•	 Fatigue is of new or definite onset
•	 Fatigue is not the result of ongoing exertion
•	 Fatigue is not the result of an organic disease
•	 Fatigue is not alleviated by rest
•	 Fatigue results in a substantial reduction in previous occupational,
 educational, social and personal activities
•	 Four or more additional symptoms, concurrently present more than 6 months
  - impaired memory or concentration - sore throat
 - tender cervical or axillary lymph nodes - muscle pain
 - new headaches - pain in several joints 
 - unrefreshing sleep - malaise after exertion
Exclusion criteria
•	 Medical condition explaining fatigue
•	 Major depressive disorder (melancholic or with psychotic features) or bipolar disorder
•	 Schizophrenia, dementia, or delusional disorder
•	 Alcohol or other substance abuse within 2 years before onset 
•	 Anorexia nervosa or bulimia nervosa
•	 Severe obesity (body mass index ≥ 40)
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
bulimia have been resolved more than 5 years before the onset of chronic fatigue, 
these conditions should not be considered exclusionary. 
Second, fatigue is a known symptom in various psychiatric disorders such as 
depression, dysthymia, panic disorder and posttraumatic disorder, and thus 
psychiatric disorders should be considered in the list of differential diagnoses of 
CFS. As there is an overlap between symptoms in CFS and psychiatric disorders, 
thorough assessment is required to minimise over and underdiagnoses of both 
CFS and psychiatric disorders. Devasahayam et al.14 explored the prevalence of 
alternative diagnosis in patients referred with a definite or provisional diagnosis of 
CFS to a specialised CFS clinic. The authors found that 49% of the referred patients 
had alternative diagnoses to CFS. The most common somatic diagnoses assessed 
were sleep disorders and the commonest alternative psychiatric diagnosis was 
depressive disorder. 
 If fatigue is part of a current clinical axis-1 psychiatric disorder and the 
psychiatric disorder is a sufficient explanation for fatigue complaints, CFS cannot 
be diagnosed and a psychiatric disorder should be diagnosed and treated 
accordingly. For example: fatigue is a common symptom in depressive disorder. 
It is important to differentiate whether fatigue is a symptom of a depressive episode, 
or of CFS. In depressive disorder, depressed mood often precedes fatigue. 
A co-morbid depressive disorder can be diagnosed in 25% of CFS patients. 
 In depressive disorder, anhedonia is a core symptom. CFS patients often 
report they want to be active, but are impaired as a consequence of their chronic 
fatigue. 
Third, conditions like anxiety disorders and less severe forms of depression do 
not preclude the diagnosis of CFS. 
There may be an association or co-morbidity between CFS and psychiatric 
disorders15, and patients with CFS and co-morbid psychiatric diagnoses have 
more symptoms and disability than CFS patients without psychiatric comorbidity16. 
Skapinakis et al. reported a high level of psychiatric co-morbidity, in particular 
depression and anxiety in CFS17. Cella et al. investigated the prevalence of 
depression and anxiety disorder in CFS. In a total of 640 CFS patients who were 
recruited into a treatment trial investigating the effect of pacing in CFS, 54% had 
a diagnosis of CFS and no depression or anxiety disorder, 14% had CFS and 
anxiety disorder, 14% had CFS and depressive disorder and 18% had CFS and 
both depression and anxiety disorder18. 
 In 2003, our group investigated the prevalence of concomitant psychiatric 
disorders in 270 CFS patients participating in a randomised controlled trial 
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investigating the effect of Cognitive Behaviour Therapy (CBT) compared to 
support groups and natural course. A current psychiatric diagnosis was found in 
32% of the CFS patients. One current psychiatric diagnosis was found in 21% and 
two or more diagnoses in 11%. It was investigated whether psychiatric co-morbidity 
has a negative effect on treatment outcome. In this study no differences were 
found in treatment outcome or withdrawal between CFS patients with and without 
psychiatric co-morbidity when treated with CBT19. It is not fully clear whether CFS 
is associated with elevated levels of personality disorders. 
 While some studies have provided evidence for elevated rates of personality 
disorders in CFS20,21, other studies were unable to confirm a higher prevalence in 
CFS22,23. Courjaret et al. evaluated the prevalence of Diagnostic and Statistical 
Manual for Mental Disorders (DMS-IV-TR) personality disorders in CFS patients 
and in matched controls. They found no differences between the CFS sample and 
the healthy control group at the level of dimensional trait scores, number of 
personality disorder criteria and prevalence rates of personality disorders. The 
discrepant findings could be related to different methods used to assess 
personality disorders, research setting (primary, secondary, or tertiary setting, 
psychiatric care or rehabilitation setting) and use of different control groups23. 
Evaluation of chronic fatigue
A systematic evaluation of fatigue symptoms was established for the diagnosis 
and treatment of patients with unexplained fatigue24,25,26,27. In the management of 
fatigue, three categories were described: 1) acute phase (fatigue up to one month 
after first consultation), 2) sub-acute phase (fatigue during one to six months) and 
3) a chronic phase (fatigue lasting more than six months). In the acute phase the 
policy is to be expectative to one month, unless symptoms change or worsen 
during that time. 
 In the sub-acute phase, laboratory testing is useful and health-promoting 
activities should be stimulated. In the clinical evaluation, somatic and psychiatric 
disorders should be taken into account in the differential diagnosis. If in the 
chronic phase no somatic or psychiatric diagnoses have been found, it is more 
likely that CFS can be diagnosed. It is important to diagnose CFS and to provide 
psycho-education to patients, since it is useless to keep searching for somatic 
causes. 
 Moreover, patients with CFS can and should be offered evidence-based 
treatment28.
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Model of CFS
In the early days, most of the research was devoted to finding a unifying patho -
genesis, i.e., one virus, one metabolic disorder and so on. These research efforts 
failed. 
 The Expert Centre for Chronic Fatigue realised that it might be more fruitful to 
discern between predisposing factors, precipitating factors and perpetuating and 
prognostic factors. 
 Predisposing factors are risk factors that make people vulnerable to develop 
CFS. Early life adverse experience (physical or emotional abuse or neglect), being 
female and physical inactivity have been reported as risk factors for CFS29,30. 
There is evidence that some genetic disposition exist for CFS29. Twin studies have 
supported modest genetic contributions to CFS31.
 Precipitating factors are somatic and psychological stressors that can trigger 
CFS symptoms. It was considered highly likely that various factors (a diversity 
of infectious agents, exposure to toxins, anaesthesia, trauma, lost of job or 
bereavement) could act as precipitating factors29. Concerning perpetuating 
factors, no satisfactory somatic factors could be identified over the years, but 
based on a rather large dataset it was possible to develop and test an empirically 
supported model of the perpetuating psychological factors in CFS (see Figure 1). 
Figure 1   The model of perpetuating factors by Vercoulen et al. (1998) 
and Prins et al. (2004).
Sense of
control FATIGUE
Somatic
attribution  
Physical
activity Focusing on
symptoms 
Social support
and reactions of others
IMPAIRMENT
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According to this model, negative cognitions and unhealthy behaviour are the 
maintaining factors in CFS. Attributing CFS symptoms to a somatic cause lowers 
physical activity, which in turn increases fatigue and leads to impairment. A low 
sense of control and focusing on bodily symptoms have a negative influence on 
fatigue32. Prins et al. in 2004 identified a perceived lack of social support as 
another perpetuating factor of fatigue severity and impairment in CFS33. 
CBT for CFS was developed based on the model of perpetuating factors. CBT is 
an effective and evidence-based treatment for CFS28,34,35. Wiborg et al. found that 
the effect of CBT for CFS was not mediated by a persistent increase in physical 
activity36, but mediated by a decrease in focusing on fatigue37.
Pathophysiology of CFS
The fact that psychological factors play a role and that CBT is effective does not 
preclude the importance of somatic factors and a somatic substrate. It should be 
noted that, despite many efforts, no drug treatment for CFS has proven efficacy35. 
Our research group therefore continues to investigate the pathophysiology of 
CFS, biological hypotheses and pharmacological treatment strategies. Many 
biological mechanisms have been postulated, but, as previously stated, none of 
these have been proven. More insight into the neurobiology of CFS is highly 
necessary to improve our understanding of this illness. CFS is probably a hetero - 
geneous condition. Neuroendocrine pathways and neurotransmitter metabolism 
have been important targets for CFS research38, and in particular disturbances in 
the growth hormone/ insulin-like growth factor-1 axis and in the serotonin system 
have been suggested to be relevant for CFS. 
 The major challenge for this thesis is to explore the evidence for neurobiological 
disturbances in CFS by using pharmacological interventions. As a result, four 
studies are presented in which the role of serotonin and the growth hormone/ 
insulin-like growth factor-1 axis are investigated to elucidate the pathogenesis of 
CFS.
Serotonin and CFS
One pharmacological study, performed by our Nijmegen research group, concerned 
the effect of Fluoxetine, a serotonin (5-hydroxytryptamine, 5-HT) re-uptake 
inhibitor. In this randomised placebo-controlled clinical trial, CFS patients with 
and without a major depressive disorder were treated with Fluoxetine39. Fluoxetine is 
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
considered to be an effective antidepressant. It turned out, in contrast to 
expectations, that the clinical trial showed neither a beneficial effect on depression 
severity, nor on fatigue severity or on any CFS-related symptoms. 
 Differences in underlying processes of depressive symptoms between CFS 
patients with depressive co-morbidity and patients with major depressive disorder 
were thought to explain these unexpected findings. 
This pharmacological study was the first study performed by the Expert Centre 
involving the 5-HT system. The results did not provide support for a role of 
serotonin reuptake inhibition in the treatment of CFS. 
 Serotonin plays a diverse and important role in the regulation of sleep and 
wakefulness, mood regulation, impulse control, memory, perception of pain and 
in behaviour that involves a high cognitive demand40. Serotonin pathways are 
widespread and project to the (frontal) cortex, striatum, hippocampus and the 
hypothalamus (see Figure 2). 
Figure 2   Serotonin system.
Dumont G. Acute effecten van selectieve serotonine-heropnameremmers: een behandeling van het 
premenstrueel syndroom. 2013;1:36-39.
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There is clinical and experimental evidence implicating enhanced serotonergic 
neurotransmission in fatigue states41,42,43. When the level of brain 5-HT is increased 
either by exercise or administration of the 5-HT precursor tryptophan, an increase 
of fatigue is observed44,45,46. In animals, tryptophan injection into the blood or 
directly into the central nervous system accelerates exhaustion during motor 
activity47. The time to exhaustion is decreased by administering a 5-HT agonist 
and increased by serotonin antagonists48.
 Accumulating evidence would support that 5-HT neurotransmission may be 
altered in CFS. 5-HT pathways from the dorsal raphe nuclei to the paraventricular 
nucleus of the hypothalamus are thought to bring about the secretion of hypo-
thalamic-pituitary-releasing peptides involved in the release of prolactin and 
ACTH (adrenocorticotropic hormone) from the anterior pituitary.
Measuring prolactin and cortisol responses to 5-HT agonist drugs probably reflect 
hypothalamic-5-HT neurotransmitter function. Although it is well-established that 
the paraventricular nucleus of the hypothalamus is under serotonergic control, 
serotonin may have a direct action on the anterior pituitary and the adrenal cortex, 
thus directly stimulating both ACTH and cortisol release49. Neuroendocrine 
challenge studies have suggested a reduced function of the Hypothalamic- 
Pituitary-Adrenal (HPA) axis and an enhanced 5-HT function in CFS50. 
Weaver et al.51 assessed serotonergic activity indirectly through assessment of 
the plasma prolactin response to intravenous tryptophan in patients with CFS with 
and without co-morbid fibromyalgia. Upregulated plasma prolactin responses 
were found only in women with CFS without co-morbid fibromyalgia. 
 The authors stated that, despite syndromal overlap between the two conditions, 
fibromyalgia has an opposite, deficient central serotonergic regulation in contrast 
to an upregulated serotonergic activity in CFS. Consequently, the presence of 
co-morbid fibromyalgia may have confounded earlier serotonin challenge studies 
in CFS patients.
Besides serotonin challenge studies, many researchers have studied the HPA 
axis in CFS patients. One of the most consistent findings is a reduced basal 
glucocorticoid cortisol output (in conjunction with enhanced ACTH production) in 
at least some CFS patients, this is most consistently shown by 24-h urinary free 
cortisol measurement. No evidence of a primary dysfunction of the HPA axis is 
found in CFS38,52. 
 It is likely that several other factors, including inactivity, medication and 
ongoing stress, influence the HPA-axis53. There is however some evidence that 
reduced cortisol levels are linked to symptom production or persistence. 
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 Roberts et al. investigated the effect of hypocortisolism on the effect of CBT 
in CFS. A weak correlation was found between low basal cortisol levels and higher 
disability scores in untreated CFS patients. Patients with a lower basal cortisol 
level responded less well to CBT54. Hypocortisolism can normalise after CBT in 
adolescents55 and adults54. There is a complex interaction between the HPA axis 
and the serotonin system. Studies have demonstrated that glucocorticoids may 
have an inhibitory effect on central serotonin function56. In depression, HPA 
system upregulation and 5-HT downregulation are prominent neuroendocrine 
hypotheses. Contrasting neuroendocrine responses have been found between 
depression and CFS: whereas CFS may be associated with reduced HPA activity 
and increased serotonin function, depression shows the reverse pattern50,57.
 Positron Emission Tomography studies58,59 and genetic studies60 have 
strengthened the hypothesis of an upregulated serotonin system in CFS. 
Growth Hormone/ Insulin-like Growth Factor-1 and CFS
The integrity of the Growth Hormone/ insulin-like growth factor system has been 
an important area of study in CFS. An important reason is the known link between 
Growth Hormone (GH) deficiency and fatigue. GH deficiency in adults is 
associated with clinical symptoms such as fatigue and myalgia61. Insulin-like 
growth factor-1 (IGF-1), also known as somatomedin C, is synthesised in peripheral 
tissues and largely in the liver. More than 99% of IGF-1 that circulates in serum 
is protein-bound. The most important binding protein is IGF-binding-protein- 
number 3 (IGF-BP-3). IGF-BP-3 is the most abundant form in plasma with the 
highest affinity for IGF-1. IGF-1 and IGF-BP-3 plasma concentrations are influenced 
by growth hormone (GH), along with other factors such as age, gender, nutritional 
status and other hormones, including insulin. 
 Unlike growth hormone, IGF-1 and IGF-BP-3 levels exhibit less daily fluctuation. 
Determining IGF-1 as well as IGFBP-3 levels is recognised as an effective test for 
assessing GH status. Abnormalities in the GH/ IGF-1 axis have been reported, but 
patient characteristics and data have not always been elaborately in these studies. 
The small number of previously investigated CFS patients may also have played 
a role in interpreting results. 
Baseline function, dynamic testing and treatment replacement studies have been 
performed. A few studies suggested low basal growth hormone and IGF-1 in 
CFS62,63. There is some evidence that basal growth hormone release is reduced 
nocturnally in CFS patients64. Di Giorgio et al. highlighted the lack of GH/ IGF-1 
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studies adequately examining GH and IGF-1 levels across the circadian cycle with 
frequent sampling intervals65. 
 In summary, reports investigating the integrity of the GH/ IGF-1 system in CFS 
have yielded conflicting results50.
Outline of this thesis
Given the controversies and uncertainties surrounding these potentially important 
mediators in CFS, we decided to investigate the role of tryptophan, 5-HT and 
IGF-1 in CFS in this thesis. Our studies aim to obtain a deeper insight into 
the pathophysiology of CFS by investigating the efficacy of three biological 
interventions for CFS.
The effect of Granisetron, a 5-HT3 receptor antagonist, in CFS
In chapter 2 we asked the question whether treatment with a 5-HT3 receptor 
antagonist is effective in CFS. Studies and clinical observations suggested a role 
for 5-HT3 receptor antagonism in the treatment of chronic fatigue associated with 
chronic liver disease66 and fibromyalgia67. The effect of 5-HT3 receptor antagonists 
in CFS patients had not been investigated in CFS patients before, hence a pilot 
study was carried out to investigate the effect of Granisetron.
The effect of Ondansetron, a 5-HT3 receptor antagonist, in CFS
In chapter 3 we addressed the same question based on positive findings found in 
the pilot study described in chapter 2. A randomised double-blind controlled trial 
was performed. Because granisetron was no longer available at that time, due to 
a merge of pharmaceutical manufacturer SmithKline Beecham with Glaxo 
Wellcome, the 5-HT3 antagonist Ondansetron (Zofran) was used to further 
investigate the effect of 5-HT3 receptor antagonism in CFS. 
The effect of Acute Tryptophan Depletion in CFS
Besides intervention with selective serotonin antagonists, we also investigated 
the effect of Acute Tryptophan Depletion (ATD), a well-known intervention in major 
depressive disorder. 
 The results of a placebo-controlled cross-over ATD study are presented in 
chapter 4. 
 Based on the hypothesis that CFS represents a hyperserotonergic state, we 
used ATD to decrease central serotonin availability, and assessed the effects on 
fatigue severity, concentration and mood.
Processed on: 3-10-2016
505445-L-bw-The
21
1
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
The effect of Acclydine in CFS
In chapter 5 we investigated whether CFS patients have lower IGF-1 levels than 
age, weight and gender matched neighbourhood controls. Based on the idea that 
the growth hormone metabolism is disrupted in CFS, De Meirleir in 2001 reported 
that treatment with Acclydine, a plant-sourced alkaloid, is effective in modifying 
growth hormone/ IGF-1 status in adult CFS patients and reverts complaints68. In 
2002, the CFS patient organisation reported in their ‘MEdium Journal’ that the 
manufacturer of Acclydine had found that 75-80% of CFS patients have a growth 
hormone deficiency69. 
 Double-blind randomised controlled trials were needed. Acclydine was an 
expensive treatment and is available on the internet without a prescription. It had 
been mentioned on the news that Acclydine was recommended for cancer 
patients with chronic fatigue, and that there were conflicts in Acclydine research70,71. 
 Acclydine was administered to vulnerable patients, but the scientific evidence 
for efficacy was lacking. The effect of Acclydine, officially a food supplement, was 
thus evaluated in a randomised controlled clinical trial. We evaluated whether 
Acclydine is effective in CFS by increasing biologically active IGF-1 levels. Results 
of a randomised controlled trial are presented in this thesis. 
Discussion and future prospects
In chapter 6 I will discuss the main results and implications of the investigations 
performed, and present recommendations and prospects for future studies. 
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Abstract
Objective: 
To explore the effect of granisetron, a 5-HT3 antagonist, on fatigue and functional 
impairment in patients with chronic fatigue syndrome (CFS).
Methods: 
Five female patients were eligible to receive oral granisetron for one month 
(1 mg a day for the first two weeks and 2 mg a day for the second two weeks). 
The patients had to be between 18 and 65 years of age and suffering from CFS 
according to the CDC criteria. The effect was assessed by pre- and post-testing, 
using validated instruments designed to assess the different dimensions of CFS. 
Treatment response was also evaluated by visual analogue scales (VAS) for 
fatigue. Analysis was based on intention to treat.
Results: 
Treatment with granisetron resulted in significant improvement in fatigue severity 
and functional impairment. Activity level showed no significant increase.
Conclusion: 
The promising results of this study have encouraged us to perform a placebo- 
controlled, double-blind study to evaluate the efficacy of 5-HT3 receptor 
antagonists in the treatment of CFS.
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Introduction
Chronic fatigue syndrome (CFS) is a medically unexplained syndrome, characterised 
by severe disabling fatigue for a period of at least six months, which has led to 
considerable impairment in daily functioning.1 Various accompanying symptoms 
may be present, such as headache, joint and muscle pain, sore throat, and 
impaired memory and concentration. Of the many therapeutic interventions that 
have been undertaken so far, only cognitive behaviour therapy (CBT) and graded 
exercise therapy (GET) have met with succes.2,3
There is accumulating data in the literature supporting an important role for 
serotonin (5-hydroxytryptamine) in the neurobiology of CFS. Neuropharmacological 
studies point to an upregulated serotonin system.4-7
In a randomised controlled trial by our own research group, the selective serotonin 
reuptake inhibitor (SSRI) fluoxetine proved to be ineffective in CDC-diagnosed 
CFS subjects for the treatment of fatigue and depression,8 which is also in line 
with upregulation of the serotonin system. Positive reports of the use of serotonin 
inhibitors in the treatment of patients with fatigue (due to chronic hepatitis9 and to 
fibromyalgia10,11) support an effect. Based on these findings, we hypothesise that 
a serotonin antagonist could be effective in CFS. Therefore, we undertook this 
pilot study.
Materials and methods
Patients
Five female CDC-diagnosed patients with a high fatigue level and a substantial 
impairment in daily life, reflected by the Checklist Individual Strength (CIS)12,13 and 
the Sickness Impact Profile-8 (SIP-8),14,15 were treated with granisetron. The cut-off 
point of the CIS fatigue severity subscale was set at 40 and the weighted total 
score of the SIP-8 was set at 800.
In a CBT multicentre, randomised controlled trial by our research group, the CBT 
treatment protocol did not seem to be suitable for a group of CFS patients with 
low activity patterns.2 Therefore, we selected patients with a low activity pattern. 
Patients whose average daily physical activity scores stayed below the reference 
score in at least nine of the twelve assessment days could be included.16 
The activity level was assessed prior to the treatment period with an actometer. 
We chose only female subjects, because in CFS the ratio male/female is 
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approximately 1:417 and combined with low activity as a disease characteristic, 
we created a homogeneous group.
Additional criteria were patients aged between 18 and 65 years, and no previous 
or current engagement in CFS research. Pregnant or lactating women and 
patients who were taking psychotropic medications were excluded. We received 
ethical clearance to perform a pilot study and obtained written informed consent 
from all patients.
Design and procedures
There were four evaluation moments (E1-E4): E1 at baseline, E2+E3, in the middle 
and at the end of the treatment period and E4 at follow-up, two weeks after the 
treatment period. The treatment period was divided in two periods of two weeks. 
During the first period, the patients received an oral dose of granisetron of 1 mg 
a day. After two weeks the effect, compliance and side effects were evaluated. 
If the evaluation showed no significant improvement, the dose was increased to 
2 mg a day.
Analysis was based on intention to treat. A linear model for repeated measures 
was used to analyse the effect of granisetron on the outcome measures CIS 
fatigue severity, CIS activity and SIP-8.
 The four evaluation moments were analysed as well as the three evaluation 
moments during the medication period. The visual analogue scales (VAS) actual 
fatigue scores were analysed by the Wilcoxon signed-rank test.
Assessments
Fatigue severity
The Checklist Individual Strength (CIS) is a reliable and validated self-report 
questionnaire. We used the subscale fatigue severity of the CIS (CIS fatigue 
severity).12,13 The score on this eight-item scale ranges from 8 (no fatigue) to 56 
(maximally fatigued).
CIS fatigue severity analysis during the medication period (E1-E3) calculated a 
significant decline in time (p=0.046). The significant drop during the medication 
period (E1-E3) means that patients reported significantly lower fatigue levels after 
treatment with granisetron. Analysis over four measurements is significant in time 
as well (p=0.026). Follow-up (E4) showed an increase in fatigue severity after 
discontinuation of granisetron (figure 1).
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Visual analogue scales (VAS) (100 mm) are used to determine the actual fatigue 
severity. VAS ratings were used to evaluate the one-month treatment period. VAS 
assessments took place during the medication period (E1, E2 and E3).
The VAS actual fatigue showed a significant drop of 29% in the mean fatigue 
scores (p=0.042) during the treatment period (table 1).
Figure 1   Effect of granisetron in five patients on the outcome variable fatigue 
severity (CIS).
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Table 1   Effect of granisetron in five patients on the outcome variable VAS 
actual fatigue severity (p=0.042)
Treatment VAS mean SD SEM Range mm
E1 – actual 76.4 13.7 6.1 59-95
E2 – actual 65.2 21.4 9.6 34-93
E3 – actual 54.4 28.1 12.6 22-92
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Functional impairment
The sickness impact profile (SIP-8) measures the influence of symptoms on daily 
functioning, using the following eight subscales to rate both physical and 
psychological disability: home management, mobility, alertness behaviour, sleep/
rest, ambulation, social interactions, work and recreation, and pastimes.14,15
 SIP-8 analysis during the medication period (E1-E3) showed a significant decline 
in time (p=0.008). Patients reported significantly less functional impairment 
during the one-month medication period. Analysis over four measurements is 
significant in time as well (p=0.005). Follow-up (E4) showed an increase in 
functional impairment after discontinuation of granisetron. Within two weeks the 
mean SIP-8 score returned to the baseline level (figure 2).
Figure 2   Effect of granisetron in five patients on the outcome variable functional 
impairment (SIP-8).
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Activity level
The actometer is a small motion-sensing device that can register and quantify 
human physical activity.18 Three different activity patterns can be distinguished for 
patients with CFS: pervasively passive, fluctuating active and pervasively active. 
In an earlier study identifying physical activity patterns in CFS patients, we 
observed that healthy controls do not fall in the category of pervasively passive. 
Patients wore the actometer day and night for a two-week period. After the 
two-week period the average scores over 12 days were computed.16
Before treatment the mean actometer score was 44.6 (SD 22.2). During the last 
two weeks of the treatment period the mean actometer score was 46.2 (SD 20.3). 
Granisetron did not significantly change the mean actometer score (p=0.16).
The subscale activity of the CIS was used (CIS activity). The score on this 
three-item scale ranges from 3 (no activity) to 21 (maximally activity level).12,13
Analysis of the CIS subscale activity showed no significant improvement during 
the medication period (p=0.16). Analysis over four measurements is not significant 
in time either (p=0.191).
Results
The five women had a mean age of 34 years (range 23-44 years). Three of the five 
patients had a pervasively passive actometer pattern. Two patients had activity 
level scores lower than the mean CFS score for 9 out of the 12 days. All patients 
finished their study.
In the first two weeks the oral dose of 1 mg granisetron was well tolerated, but 
none of the patients showed significant improvement. In the second period all 
patients received 2 mg granisetron a day.
Four out of five patients reported marked improvement. One patient did not report 
any improvement on the outcome variables fatigue severity, activity level and 
functional impairment. Another patient complained of constipation as a side 
effect of granisetron during the last few days of the treatment.
Processed on: 3-10-2016
505445-L-bw-The
34
CHAPTER 2
Discussion
In this pilot study we evaluated the effect of granisetron, a serotonin receptor 
antagonist, in chronic fatigue syndrome patients with low activity patterns. We 
found a substantial decrease in fatigue and functional impairment in four out of 
five patients as assessed by CIS fatigue severity, SIP-8 and visual analogue scale. 
That these changes in scores are clinically relevant can be deduced from our 
observations that these patients and their partners reported a remarkable 
improvement in fatigue and functional impairment at the end of the treatment 
period.
That granisetron, a serotonin antagonist, could have a favourable effect in CFS 
is not totally unexpected. First of all, there are reports in the literature pointing to 
a postsynaptic hyper-responsiveness in CFS.4,5 Also the challenge test with 
buspirone, a 5-HT agonist and D-fenfluramine, a serotonin reuptake inhibitor, 
met with exaggerated prolactine responses in CFS patients, consistent with a 
postsynaptic serotonergic hyper-responsiveness in CFS.6,7
Second, there are reports in the literature pointing to a favourable effect of 
serotonin antagonist in fatigued patients. Jones reported a positive effect on 
fatigue in a 35-year-old woman with profound fatigue associated with chronic 
hepatitis-C when treated with a 5-HT3 receptor antagonist.9 Positive results in 
fibromyalgia studies10,11 also support a favourable effect of serotonin antagonists 
in the treatment of fatigue.
A remarkable finding is that within two weeks after dis-continuation of granisetron, 
follow-up showed a marked increased mean fatigue level score and an increased 
functional impairment score. Within a few days granisetron is eliminated from the 
system (T1/2 elimination is 9-12 hours). The increase in symptoms within a short 
period after discontinuation of the medication supports the hypothesis that the 
intervention with granisetron is responsible for the reported improvement.
In this open study, a placebo effect cannot be excluded. However, in previous 
placebo-controlled studies8,19 we have not encountered remarkable changes in 
fatigue severity and functional impairment in the placebo group. The actometer 
activity level showed no significant improve-ment. A possible explanation is that a 
reduced level of fatigue will not immediately lead to an increased physical walking 
activity level, which is measured by the actometer. It is possible that CFS patients 
have quite structured daily routines. A reduced level of fatigue will probably not 
immediately lead to a change in the daily routines. We treated patients with low 
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activity patterns. In addition there may be deconditioning of the patients, which is 
not reversible in the short term of one month. It might take more than four weeks 
to change the rather static activity patterns, despite a decreased level of fatigue. 
Perhaps a longer treatment protocol and a longer registration period could lead 
to (significantly) improved actometer activity levels. However, we do not know 
whether wearing off effects occur with prolonged treatment.
It is striking that the outcome measures showed an improvement of CFS-related 
symptoms after two weeks (figures 1 and 2). It is not clear whether the reported 
improvement after two weeks can be explained by a dose-dependent effect. 
A possible explanation is that time is a key factor in the reported improvement. 
It is possible that granisetron induced a postsynaptic receptor modification in 
time or decreased the sensitivity of the postsynaptic receptors.
Data in the literature point in the direction that CFS and depression are opposing 
disease entities with contrasting neuroendocrine responses and 5-HT functioning.20-22 
The ‘serotonin hypothesis’ is the most widely accepted neural basis for depression. 
Drugs that preferentially increase serotonin activity by decreasing its reuptake 
(selective serotonin reuptake inhibitor, or SSRI) are effective in the treatment of 
depression23-25 and not in the treatment of CFS, even when the patients are 
depressed.8
It is worth noting that there is a therapeutic delay of two weeks in the treatment of 
depression with a SSRI. It is conceivable that a similar delay occurs with 5-HT 
receptor antagonism as applied in the presented study.
It is remarkable that one patient did not respond. This 23-year-old woman with a 
CFS history of three years was no different from the other patients with regard to 
her history, CDC criteria, CIS fatigue severity score and SIP-8 score.
Whether such nonresponsiveness has a serotonergic neuroendocrine basis has 
to be investigated in longer studies combined with serotonergic challenge tests 
and with serotonin receptor-status imaging studies. It is known that granisetron 
concentrations in blood may vary between subjects. A lower granisetron concentration 
might have caused the nonresponse in this individual. In this pilot study we did 
not measure blood granisetron concentrations. An interesting question is also 
whether further dose escalation would enhance the effect.
Our favourable results in this pilot study warrant a study with a randomised placebo- 
controlled, double-blind design. 
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At the present time we are conducting such a randomised clinical trial with a 
longer treatment protocol and longer registration periods. In the future an interesting 
treatment concept might be a combination of a 5-HT3 receptor antagonist with 
CBT or GET.
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Abstract
Background:
Accumulating data support the in-volvement of the serotonin (5-hydroxytrypt-
amine [5-HT]) system in the pathophysiology of chronic fatigue syndrome. Neu-
ropharmacologic studies point to a hyperactive 5-HT system, and open-label 
treatment studies with 5-HT3 receptor antagonists have shown promising results. 
In this randomized controlled clinical trial, the effect of ondansetron, a 5-HT3 
receptor antagonist, was assessed on fatigue severity and functional impairment 
in adult patients with chronic fatigue syndrome.
Method:
A randomized, placebo-controlled, double-blind clinical trial was conducted at 
Radboud University Nijmegen Medical Centre, The Netherlands. Sixty-seven 
adult patients who fulfilled the US Centers for Disease Control and Prevention 
(CDC) criteria for chronic fatigue syndrome and who were free from current 
psychiatric comorbidity participated in the clinical trial. Participants received 
either ondansetron 16 mg per day or placebo for 10 weeks. The primary outcome 
variables were fatigue severity (Checklist Individual Strength fatigue severity 
subscale [CIS-fatigue]) and functional impairment (Sickness Impact Profile-8 
[SIP-8]). The effect of ondansetron was assessed by analysis of covariance. Data 
were analyzed on an intention-to-treat basis. All patients were recruited between 
June 2003 and March 2006. 
Results: 
Thirty-three patients were allocated to the ondansetron condition, 34 to the 
placebo condition. The 2 groups were well matched in terms of age, sex, fatigue 
severity, functional impairment, and CDC symptoms. Analysis of covariance 
showed no significant differences between the ondansetron- and placebo-treat-
ed groups during the 10-week treatment period in fatigue severity and functional 
impairment.
Conclusions: 
This clinical trial demonstrates no benefit of ondansetron compared to placebo
in the treatment of chronic fatigue syndrome.
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Background
Chronic fatigue syndrome is a medically unexplained syndrome, characterized by 
severe disabling fatigue for a period of at least 6 months that has led to considerable
impairment in daily functioning.1 Various accompanying symptoms may be present, 
such as headache, joint and muscle pain, sore throat, and impaired memory and 
concentration. In The Netherlands, a country with 16 million inhabitants, there are 
probably between 30,000 and 40,000 patients with chronic fatigue syndrome.2 
Of the many therapeutic interventions that have been undertaken, so far only cognitive 
behavioral therapy and graded exercise therapy are of proven effectiveness.3,4
Neuroendocrinologic investigations have tried to elucidate the pathophysiology 
of chronic fatigue syndrome.5 Data in the literature support an important role for 
serotonin (5-hydroxytryptamine [5-HT]) in the pathophysiology of chronic fatigue 
syndrome.6–8 Serotonin plays a diverse and important role in the regulation of 
sleep and wakefulness, mood regulation, impulse control, memory, and perception 
of pain and in behavior that involves a high cognitive demand.9 Increased activity 
or metabolism of the 5-HT system have been implicated in the pathophysiology of 
chronic fatigue syndrome.10–13 An increased 5-HT metabolism in fatigue is 
supported by a rise in plasma tryptophan, the precursor of 5-HT during and after 
sustained exercise in healthy persons.14–16
Positive results of the use of 5 -HT3 inhibitors in the treatment of patients with 
chronic fatigue due to chronic hepatitis17,18 or fibromyalgia19,20 are in line with a role 
of serotonin in fatigue and support further research into this type of pharmacologic 
interventions.
Results of an open-label pilot study performed by our research group showed 
positive results during 1-month treatment with granisetron, a 5-HT3 receptor 
antagonist.21 The results of the pilot study encouraged us to investigate the effect 
of ondansetron in a well-defined chronic fatigue syndrome population using 
validated outcome measures in a randomized, double-blind, placebo-controlled 
design.
Method
The study was approved by the medical ethical committee of the Radboud 
University Nijmegen Medical Centre. Written informed consent was obtained from 
all participants prior to enrollment.
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Participants
Patients were recruited through the outpatient clinic of the Department of General 
Internal Medicine of the Radboud University Nijmegen Medical Centre. 
Furthermore, patients with chronic fatigue syndrome who were referred by general 
practitioners to the Nijmegen Expert Centre Chronic Fatigue for treatment were 
also asked to participate in the clinical trial. Patients were eligible for participation 
if they met the following inclusion criteria: aged between 18 and 65 years, 
satisfying the 1994 US Centers for Disease Control and Prevention (CDC) 
consensus criteria for chronic fatigue syndrome,1 and scoring above clinical 
cut-off on the Checklist Individual Strength fatigue severity subscale and the 
Sickness Impact Profile-8 (see below).     
At the end of 2003, the International Chronic Fatigue Syndrome Study Group 
presented recommendations for better application of the 1994 case definition of 
chronic fatigue syndrome.22 The 1994 CDC criteria for defining chronic fatigue 
syndrome have been superseded by the revised 2003 CDC criteria. In our clinical 
trial, we did not use the 2003 CDC criteria because the inclusion of the study 
started before the publication of the revised 2003 CDC criteria. The Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID-I)23 was performed by the 
investigator with a clinical background, who was trained in the SCID-I interview, to 
exclude patients with current psychiatric co-morbidity. Pregnant or lactating 
women were excluded, as were patients with lactose intolerance and patients 
taking psychotropic drugs or experimental medications.
Interventions
Ondansetron (8-mg tablets) and an identical placebo were delivered by the 
manufacturer GlaxoSmithKline, The Netherlands. There was no difference in 
taste, appearance, or packaging between the active supplements and the placebo 
tablets. During 10 weeks, the chronic fatigue syndrome patients took either 
ondansetron (two 8 -mg ondansetron tablets) or 2 placebo tablets at night. The 
dose of 16 mg per day was based on the results of the pilot study performed 
before this clinical trial.21 In the pilot study, we observed a positive treatment effect 
with an equipotent dose of 16 mg ondansetron per day at night, and the patients 
tolerated the medication relatively well Späth et al24 reported positive effects in 
patients with chronic fatigue syndrome treated with 16 mg per day, as well.
Design and Procedures
The study was a prospective, randomized, double-blind, placebo-controlled trial. 
The study was fully designed by the investigators and executed independently of 
the manufacturer of the study drugs.
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The outcome measures were assessed before the start of the pharmacologic 
interventions and at the end of the 10-week treatment period, when the patients 
were still taking the medication. All participants, investigators, and laboratory 
technicians were blinded to the treatment condition.
Randomization
Before the start of the clinical trial, the hospital pharmacy prepared 70 treatment 
packages. Randomization and allocation to the treatment or placebo group was 
based on a patient’s study number. The pharmacy held the randomization list that 
correlated the study number with the treatment group. To maintain balance over 
time, the concealed randomization was done in blocks of 10. Treatments were 
generated randomly within the blocks using a computer program (Excel, 
Microsoft, Redmond, Washington, http:// www.microsoft.com). After acceptance 
of a patient by the junior researcher (G.K.H.T.) and the clinical psychologist (G.B.), 
the eligible patient received the lowest study number available (1–70).
Primary Outcome Measures
Fatigue severity 
The Checklist Individual Strength is a reliable and validated self-report questionnaire. 
We used the Checklist Individual Strength fatigue severity subscale (CIS-
fatigue).4,25,26 The score on this 8-item scale ranges from 8 (no fatigue) to 56 
(maximally fatigued). 
The cut-off point for severe fatigue was set at 35.27 Patients who had chronic 
fatigue syndrome with a fatigue severity score of 35 or higher were included.
Functional impairment 
The Sickness Impact Profile-8 (SIP-8) measures the influence of symptoms on 
daily functioning, using the following 8 subscales to rate both physical and 
psychological disability: home management, mobility, alertness behavior, sleep/
rest, ambulation, social interactions, work, and recreation and pastimes.4 A total 
score was calculated by addition of the weights of items. This widely used 
measure has good reliability and validity.28 Patients with chronic fatigue syndrome 
with substantial functional impairments, ie, a score of 800 or higher, were included.
Patients had to fulfill both the fatigue severity and functional impairment criteria to 
participate in the study.
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Secondary Outcome Measures
Activity level
Besides self-reported outcome measures, we measured physical activity with an 
actometer (Medical Instruments Services, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands).29 An actometer is a small motion-sensing 
device that can register and quantify human physical activity. The actometer is 
attached to the ankle; it was worn continuously for 12 consecutive days and nights 
during the assessment periods. It consists of a piezo-electric sensor that is 
sensitive in 3 directions, and it detects movements of the leg (eg, during walking 
or climbing stairs). Accelerations of the sensor above a predefined threshold are 
considered as activity and are stored into an internal memory of the actometer. 
Each second, the counter of the actometer is read and reset by the micro 
controller, which adds the value to the integration counter. The integration counter 
is set at 5 minutes, providing every 5 minutes an activity score that is stored into 
the internal memory of the actometer. A general physical activity score that 
expressed the mean activity level over the 12 days in the mean number of 
accelerations per 5-minute interval was calculated.30,31
Daily fatigue level 
During the 2-week actometer period, patients rated their fatigue levels in a diary. 
They rated their levels of fatigue 4 times a day on a 0 (no fatigue) to 4 (maximally 
fatigued) scale. The 4 scores for each day were summed to produce the daily 
observed fatigue (DOF) score, which ranged from 0 to 16.30 The mean of 12 
consecutive DOF scores was used.
Statistical Methods
For all analyses, SPSS 14.0 (SPSS Inc, Chicago, Illinois, http://www.spss.com) 
was used. Power calculations before the start of the trial showed that 30 persons 
were needed in each group to detect a difference of at least 1 standard deviation 
(SD) on the CIS-fatigue with a power of 90% and a 2-tailed significance level of 
5%. Anticipating a dropout rate of 10%, 66 persons needed to be recruited. 
Analyses were performed on an intention-to-treat basis. Missing values were 
replaced by way of mean imputation.32 
The effect of ondansetron was assessed by analysis of covariance (ANCOVA) of 
the posttreatment scores after 10 weeks as the dependent variable, the baseline 
scores as covariate, and condition as fixed factor.33 Analyses were completed 
before the code was broken.
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Results
All patients were recruited between June 2003 and March 2006. Figure 1 illustrates 
participant flow through the trial.
Figure 1   Participant flow.
Abbreviation: CFS = chronic fatigue syndrome
Burdon of study n = 39
Did not want medication n = 20
Inconvenient timing n = 5
Other CFS treatment n = 5
(planned) pregnancy n = 4
Did not believe in CFS research
with ondansetron n = 2
Reason unknown n = 4
Current psychiatric comorbidity
 Depression n = 5
 Anxiety disorder n = 1
 Obsessive compulsive disorder n = 1
 Current treatment for CFS n = 3
Current treatment for pain n = 2
Age  n = 1
Assessed for eligibility (n = 159)
Refused participation n = 79
Not eligible n = 13 
Assigned (n = 34)
Completers (n = 34)
Assigned (n = 33)
Completers (n = 30)
Randomization (n = 67) 
PlaceboOndansetron
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In total, 159 patients were given information about the study protocol; 79 persons 
refused to participate, and the main reason given for refusal was the intensity of 
the study. Thirteen patients did not meet the inclusion criteria. Seventy-four 
patients were screened with the SCID-I Interview. Of those, 7 were excluded due 
to current psychiatric comorbidity. A total of 67 patients, without current psychiatric 
comorbidity, were allocated randomly to the ondansetron group or to the placebo 
group. The ondansetron (n = 33) and placebo (n = 34) groups did not differ with 
respect to age, gender, fatigue severity, impairment, or number of CDC symptoms 
(Table 1).
During the screening process, we obtained data from all the patients who did not 
want to participate.
 There was no significant difference in age, number of CDC symptoms, fatigue 
severity, or functional impairment between the patients with chronic fatigue 
syndrome participating in the clinical trial and those who chose not to participate 
(data not shown).
 In the placebo arm, no participants dropped out. Three patients in the 
ondansetron arm dropped out within the first 2 weeks of the trial. One patient 
agreed to participate in the posttesting assessments, and 2 patients in the 
ondansetron group had missing values for the posttreatment measurements. 
The main reason for discontinuing the trial was an increased general feeling 
of malaise. Ondansetron and placebo treatments were relatively well tolerated. 
Four patients (3 ondansetron and 1 placebo) had complaints of constipation, 
and a laxative syrup was prescribed. No other important side effects were 
reported in either group.
Table 1  Patient Characteristicsa
Ondansetron Placebo Significance
Characteristic (n = 33) (n = 34) t P
Age, y 35.8 (9.9) 34.7 (9.4) … .64
Sex, female 67 74 … .54b
CIS-fatigue 49.4 (6.3) 50.0 (4.7) 0.424 .67c
SIP-8 1,375 (470) 1,359 (593.4) 0.117 .907c
CDC symptoms 7.4 (1.4) 6.8 (2.1) 1.34 .183c
aValues are means (SD) except for sex, which is given as percentage female.
bChi-square test. cIndependent sample t test.
Abbreviations: CDC = US Centers for Disease Control and Prevention, CIS-fatigue = Checklist Individual 
Strength fatigue severity subscale, SIP-8 = Sickness Impact Profile-8.
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Primary Outcomes
Evaluation of fatigue severity and functional impairment posttreatment scores 
showed no significant differences between the ondansetron and placebo groups. 
The posttreatment scores of both groups remained in the clinical range of severe 
fatigue and substantial functional impairment.
 Our primary analysis was to impute the missing values of the 2 patients using 
mean imputation. Moreover, we performed a sensitivity analysis testing 2 imputation 
methods: first by imputing the last observation carried forward and second by 
imputing the maximum score (worst case scenario) of the primary outcome 
measures. Both imputating methods had no significant impact on the conclusions 
of the primary analysis.
Table 2   Scores on Outcome Measures and ANCOVA Results for Patients With 
Chronic Fatigue Syndrome Treated With Ondansetron or Placeboa
Ondansetron Placebo ANCOVA
(n = 33) (n = 34) (df = 1,64)
Outcome Measure Mean SD Mean SD F P
Primary outcome measures
CIS-fatigue    0.116    .73
Pretreatment 49.4 6.3 50.0 4.7
Posttreatment 44.0 11.1 45.4 11.5
SIP-8    1.077 .30
Pretreatment 1,375 470.0 1,359 593.4
Posttreatment 1,063 525.5 1,172 694.6
Secondary outcome measures
Actometer    0.773 .38
Pretreatment 54.1 16.5 58.4 16.6
Posttreatment 55.0 15.5 60.6 17.9
DOF    0.015 .90
Pretreatment 8.5 2.0 8.4 2.0
Posttreatment 7.9 2.4 7.8 2.8
Abbreviations: ANCOVA = analysis of covariance, CIS-fatigue = Checklist Individual Strength fatigue 
severity subscale, DOF = daily observed fatigue, SIP-8 = Sickness Impact Profile-8.
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Secondary Outcomes
Posttreatment actometer activity scores and DOF scores of the ondansetron and 
placebo group did not differ significantly. F-statistics and mean scores of the 
primary and secondary outcomes are shown in Table 2.
Discussion
This randomized, double-blind, controlled clinical trial investigated the therapeutic 
potential of the serotonin receptor antagonist ondansetron. We did not find 
significant differences between the ondansetron- and placebo-treated groups 
during the 10-week treatment period for any dimension of chronic fatigue 
syndrome. 
This result was rather unexpected given the promising results in an earlier open 
study in which we tested the effect of granisetron, a compound similar to 
ondansetron. Four of 5 patients showed a remarkable improvement that reversed 
after cessation of the drug.21 Of course, such an open study is prone to observer 
bias, and a placebo effect cannot be excluded. However, in earlier studies in 
chronic fatigue syndrome performed by us34,35 and others,36 placebo effects were 
minimal. Besides pharmacologic and neuroendocrine studies implicating an 
increased 5-HT neurotransmission, positron emission tomography (PET) supports 
the hypothesis of an increased serotonergic state in chronic fatigue syndrome. 
Cleare et al37 found a widespread reduction in the number or affinity of 5-HT1A 
receptors, and the results of this study may be compatible with the neuroendocrine 
studies. 
 A prolonged increased 5-HT state might result in a chronic 5-HT down- 
regulation and, consequently, reduced 5-HT binding potential.37
On the basis of all of these previous findings, the question arises why our trial met 
with negative results. We have scrutinized our study regarding potential confounding 
factors, but could not identify any. The groups were well matched, and only well- 
diagnosed patients with chronic fatigue syndrome fulfilling the CDC criteria were 
included. Furthermore, we excluded patients with current psychiatric comorbidity. 
 In this clinical study, we investigated the effect of serotonin receptor 
antagonism with ondansetron. We included patients from the outpatient clinic of 
the department of general internal medicine and patients who were referred by 
the general practitioner to the Expert Center Chronic Fatigue for treatment. 
Patients with chronic fatigue syndrome who were taking serotonergic medication 
were excluded from participating in the study. We also chose to exclude patients 
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with current psychiatric comorbidity. Methodological differences and definition 
difficulties in the literature have produced conflicting results concerning the 
prevalence of psychiatric disorders in chronic fatigue syndrome and the impact of 
psychiatric disorders on the prognosis of chronic fatigue syndrome.38 Furthermore, 
evidence suggests an important role for the neurotransmitter serotonin in psychiatric 
disorders, such as in depression39,40 and in the pathophysiology and treatment of 
anxiety and panic attacks.41,42 In this way, we reduced the chance the results will 
be biased by current Axis I psychiatric disorders. 
To our knowledge, ondansetron has no significant role in the treatment of 
depression, anxiety disorders, or obsessive-compulsive disorders.43 Therefore, 
we do not believe that excluding patients with current psychiatric comorbidity has 
reduced the likelihood of achieving response to ondansetron.
In our open-label study, we used granisetron, at that time marketed by SmithKline 
Beecham. When we were designing the present study, SmithKline Beecham 
merged with GlaxoWellcome and sold granisetron to Roche. Although this is a 
fully investigator-driven study, we were not able to obtain granisetron and placebo 
for the randomized controlled trial. Thus, we had to redesign the study and use 
ondansetron. Granisetron and ondansetron are both selective 5-HT3 receptor 
antagonists. To our knowledge, no differences in efficacy and side effects are 
described between the different 5-HT3 receptor antagonists. Given the similarities 
between the 2 drugs, we feel it is highly unlikely that the switch to ondansetron 
explains our negative results.
We did not monitor patient compliance on a daily basis. During the trial, patients 
had an appointment by telephone or at the outpatient clinic every 2 weeks. 
 During these appointments, we assessed whether patients experienced side 
effects and whether the trial medication was taken as direct-ed. Although we have 
not rigorously checked compliance, we do not believe that lack of adherence can 
explain the negative findings.
We did not assess the baseline serotonin status of the patients with chronic 
fatigue syndrome. As mentioned previously, results from neuroendocrine challenge 
studies have suggested increased central 5-HT function in patients with chronic 
fatigue syndrome. Several different 5-HT agonists have been used to assess 5-HT 
function in chronic fatigue syndrome. 
 Studies with buspirone10 and d-fenfluramine11,12 showed an enhanced prolactin 
response in patients with chronic fatigue syndrome compared to healthy controls 
and depressed subjects. Others showed a normal 5-HT activity.44,45 Appropriateness 
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of matching and selection of patients with chronic fatigue syndrome with hetero- 
geneous psychiatric history could partly contribute to the inconsistent findings in 
the 5-HT challenge studies.5 One possible explanation is heterogeneity of the 
central serotonin bio-synthetic status within the patients with chronic fatigue 
syndrome, measured as the ratio of serum tryptophan to the sum of its competing 
large neutral amino acids.46 In our study, we do not know if the patients had a high 
serotonin status. If the patients in the ondansetron treatment group had a normal 
serotonin status, one could hypothesize that receptor antagonism could not be 
effective in these patients. However, we did not see any differences in the pattern 
of response between the placebo and the ondansetron group. For example, in 
both treatment groups, an equal number of 8 patients showed an improvement 
of more than 10 points in the CIS-fatigue severity.
In our clinical trial, we could detect changes over time in both groups. We have 
assessed the effects with validated instruments designed to assess different 
dimensions of chronic fatigue syndrome as well as treatment effects. In our trials 
on cognitive behavior therapy,4,26 those instruments were robust and reliable to 
show improvement at the group level as well as at the level of the individual 
patient. The negative findings in this randomized controlled trial cannot be 
explained by a power problem. In our opinion, it is very unlikely that a larger trial 
would detect a clinically relevant effect. The lack of significant differences on 
self-report outcome measures and physical activity strengthens our overall findings.
In conclusion, this randomized, placebo-controlled trial did not demonstrate any 
benefit in chronic fatigue syndrome-related outcome measures. Thus, the findings 
of this clinical trial do not support the use of 5-HT3 antagonism in treating chronic 
fatigue syndrome–related symptoms.
Drug names: buspirone (BuSpar and others), granisetron (Sancuso, Kytril, and 
others), ondansetron (Zofran and others).
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CHAPTER 4
Abstract
Background
Chronic fatigue syndrome (CFS) is still an enigmatic disorder. CFS can be 
regarded as a complex disorder with tremendous impact on lives of CFS-patients. 
Full recovery without treatment is rare. A somatic explanation for the fatigue is 
lacking. 
There is clinical and experimental evidence implicating enhanced serotonergic 
neurotransmission in CFS. Genetic studies and imaging studies support the 
hypothesis of upregulated serotonin system in CFS.
In line with the hypothesis of an increased serotonergic state in CFS, we performed 
a randomised clinical trial investigated the effect of 5-HT3 receptor antagonism in 
CFS. No benefit was found of the 5-HT3 receptor antagonist ondansetron 
compared to placebo.
To further investigate the involvement of serotonin in CFS we performed a placebo 
controlled cross over pilot study investigating the effect of Acute Tryptophan 
Depletion.
Findings: 
Five female CFS-patients who met the US Center for Disease Control and 
Prevention criteria for CFS were recruited. There were two test days, one week 
apart. Each participant received placebo and ATD. To evaluate the efficacy of the 
ATD procedure tryptophan and the large neutral amino acids were measured. The 
outcome measures were fatigue severity, concentration and mood states.
ATD resulted in a significant plasma tryptophan to large neutral amino acid ratio 
reduction of 96%. There were no significant differences in fatigue-, depression 
and concentration between the placebo- and ATD condition.
Conclusions: 
These first five CFS-patients did not respond to the ATD procedure. 
However, a much larger sample size is needed to draw final conclusions on the 
hypothesis of an increased serotonergic state in the pathophysiology of CFS.
Trial registration: ISRCTN07518149
Keywords: Serotonin, Tryptophan, Depletion, Fatigue
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Introduction
Chronic fatigue syndrome (CFS) is characterized by severe disabling fatigue of 
at least six months duration that has led to considerable impairment in daily 
functioning. A somatic explanation for the fatigue is lacking [1].
 In the pathophysiology of CFS, several lines of evidence support the hypothesis 
of an underlying dysfunction of the serotonergic (5-hydroxytryptamine, 5-HT) 
system. In 1987 Newsholme inaugurated a possible link between an increased 
serotonin metabolism and chronic fatigue. In healthy persons exercise results in 
an increased brain 5-HT metabolism in response to an increased delivery of 
plasma tryptophan, the precursor of serotonin [2].
In CFS patients, neuroendocrine challenge studies have suggested both an 
increased [3] and normal [4] 5-HT function. These discrepancies might be 
explained by differences in methodology, composition of the patient cohort and 
the use of different 5-HT agonists [5]. Two positron emission tomography studies 
have investigated the serotonin system in CFS [6,7]. Both studies suggest an 
increased serotonin activity in CFS. A genetic study, which evaluated the 5-HT 
system in CFS, reported the 5-HT receptor subtype HTR2a −1438 A polymorphism 
to be associated with CFS. This variation in HTR2a may result in enhanced activity 
of the 5-HT system and contribute to the pathophysiology of CFS [8].
In line with the hypothesis of an increased serotonergic state in CSF, we 
investigated the effect of a 5-HT3 receptor antagonist in a small open label study 
in 5 CFS-patients and found positive effects on fatigue severity and on functional 
impairment [9]. In a subsequent randomized clinical trial in 67 patients with CFS, 
no benefit was found of the 5-HT3 receptor antagonist ondansetron compared to 
placebo [10]. An earlier placebo-controlled double-blind study with the serotonin 
reuptake inhibitor fluoxetine showed no beneficial effect on any characteristic of 
CFS, including depressive symptoms [11].
To further investigate the involvement of 5-HT in CFS, we performed a placebo 
controlled cross over pilot study investigating the effect of Acute Tryptophan 
Depletion (ATD).
ATD is a reliable and reversible challenge test for serotonin and has been widely 
used over the last decade to investigate the role of serotonin in a variety of 
psychiatric disorders [12]. We postulate that ATD would have a positive effect in 
CFS-related symptoms such as fatigue severity, concentration and mood.
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Methods
The study was approved by the medical ethical committee of the Radboud 
University Nijmegen Medical Centre. Written informed consent was obtained from 
the participants.
Five female outpatients (age mean 24.0, SD 3.5 year, range 19 to 29 year) who 
met the US Center for Disease Control and Prevention criteria for CFS, were 
recruited through the outpatient clinic of the Department of General Internal 
Medicine of the Radboud University Nijmegen Medical Centre. A structured 
Clinical interview for DSM-IV (SCID-I) was performed by the researcher, to exclude 
patients with current psychiatric co-morbidity. Exclusion criteria were: vegetarians, 
nursing women, pregnant women, use of psychotropic medication in the last 
month, previous or current engagement in CFS or psychiatric research. Patients 
were tested in the follicular phase.
We used ATD mixtures and placebo mixtures as described by Sobczak et al. 2002 
[13]. There were two test days, one week apart. On each test day, patients were 
assessed after an overnight fast. 24 hours before the test days patients had a 
tryptophan low diet [12]. Each participant received placebo and ATD. Baseline 
assessments (T0) took place at 8.30 a.m and five hours after ingestion of the 
mixtures the second assessment (T1) took place. The hospital pharmacy prepared 
the mixtures and the order of treatment was balanced over two the test days. 
The participants, investigators and laboratory technicians were blinded to the 
treatment condition.
To evaluate the efficacy of the ATD procedure, at T0 and T1, total plasma 
Tryptophan and LNAAs (phenylalanine, tyrosine, isoleucine, leucine and valine) were 
measured simultaneously after completion of the study with high- performance 
liquid chromatography as described elsewhere [14].
Outcome measures
Reliable and validated instruments were used. Current fatigue severity was 
measured by the Checklist Individual Strength, subscale fatigue severity [15]. 
 The score on this eight-item scale ranges from eight (no fatigue) to 56 (maximally 
fatigued). Current concentration was measured by the subscale CIS-concentration. 
The subscale consists of 5 items; range five (no concentration problems) to 35 
(severe concentration problems).
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The Dutch validated, shortened version of the Profile of Mood States (POMS), was 
used to assess mood changes during ATD. The subscale depression was used 
and current mood was assessed by a 5-point Likert Scale. The subscale 
depression consists of 8 items and ranges from 8 (no depression symptoms) to 
40 (high level of depression symptoms). The Dutch POMS is considered a reliable 
instrument (Cronbach’s alpha subscale depression 0.87). Strong correlations 
with other mood state and measures of depression have been found and the 
validity of the Dutch POMS is considered good [16,17]. Current fatigue, 
concentration and mood were assessed at baseline (T0) and 5 hours after 
ingestion of the mixture (T1).
 The outcome measures will be presented by means and standard deviation. 
A GLM repeated measures analysis will be performed using subject factors; time 
and ATD/ placebo.
Results
All patients drank the ATD- and placebo mixtures within 15 minutes. Besides a 
little discomfort during and just after drinking the mixtures, the patients could 
tolerate the mixtures quite well.
 ATD resulted in a significant plasma tryptophan to large neutral amino acid 
ratio reduction of 96% (data not shown). There were no significant differences in 
fatigue-, depression and concentration between the placebo- and ATD condition. 
Also, at the individual level, none of the patients presented with clear clinical 
improvements in the depleted condition (Table 1).
Table 1  Outcome measures, Mean (sd), p-value
Outcome Treatment T0 Mean (sd) T1 Mean (sd) p-value
CIS-Fatigue Placebo  36.4 (11.9)  42.2 (7.2) 0.97 (F = 0.002, df = 1)
ATD  40.0 (7.2)  46.0 (3.9)
CIS-Concentration Placebo  20.0 (10.6)  23.2 (9.9) 0.26 (F = 1,751, df = 1)
ATD  22.4 (11.4)  23.0 (11.8)
POMS-depression Placebo  8.6 (0.6)  9.6 (0.6) 0.37 (F = 1, df = 1)
ATD  9.6 (2.5)  9.4 (2.6)
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Discussion
Different lines of evidence support the hypothesis of an increased serotonergic 
state in CFS. In this pilot study we evaluated the effect of an overall serotonin 
depletion in a cross-over design in CFS-patients. Serotonin depletion was 
achieved by acute depletion of the serotonin precursor tryptophan.
There is some evidence that there is a threshold for tryptophan depletion that 
needs to be exceeded before behavioral effects occur [18]. Although ATD resulted 
in a significant (96%) reduction of the tryptophan/LNAA ratio, no improvements 
were found in CFS-related symptoms. Since ATD very probably resulted in a 
transient serotonin depletion for a few hours, one could hypothesize that a more 
prolonged 
 5-HT depletion would be necessary to achieve neurobiological 5-HT changes 
and changes in fatigue severity in a chronic condition like CFS. A prolonged 
overall increased serotonergic synaptic neurotransmission could lead to a chronic 
downregulation of 5-HT1a receptors and a reduced binding potential [7]. 
 Only a short and transient serotonin depletion would probably not lead to 
structural changes at the level of serotonin receptors. Furthermore, the most 
consistent finding of ATD is a mood-lowering response in patients recovered from 
depression [20]. To our knowledge, studies have not yet been performed 
investigating ATD effects on chronic fatigue in CFS patients; it is possible that ATD 
has a smaller impact in these patients. 
 On the other hand, ATD studies have reported fast and significant effects on 
mood patients recovered from depression, particularly in those taking serotonergic 
antidepressants [20] and in patients with social anxiety disorder [20,21]. 
Assessment took place 5 hours after ingestion of the mixtures. Plasma tryptophan 
reaches its minimum level between 5 to 7 hours after ingestion of the ATD mixture. 
 It can be understood that there is a delay from the time plasma tryptophan 
reaches the point of maximal depletion to the time of maximum serotonergic 
depletion in the brain. In this study it is not exactly known when maximum effects 
occur. 
 The study was performed in a homogeneous group of medication-free female 
CFS-patients. To avoid confounding effects of current psychiatric conditions that 
can affect brain serotonergic function we recruited CFS patients without current 
axis-1 psychiatric comorbidity. There is a group of subjects who are vulnerable to 
the effects of ATD. Patients who had previous episodes of depression or people 
with a family history of depression are vulnerable [20]. 
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In our study we did not screen in detail the patients history or the family history. 
However any undetected vulnerability for depression would have increased the 
chance for finding ATD would lead to lowering of mood. In fact, in the study we did 
not observe a mood lowering effect of ATD. A major limitation of this study is the 
small sample size. Although there was no change in any of the outcome measures 
and robust improvements at the individual level were not detected either, further 
research in larger sample sizes is needed to allow a more definite answer, 
regarding the effect of ATD in CFS. 
In conclusion, our earlier treatment study with a selective serotonin blocking 
agent as well as the present study with alimentary induction of significant ATD 
showed no positive results in any of the outcome measures in the treatment of 
CFS. Administering of ATD in a much larger sample size is needed to draw final 
conclusions on the hypothesis of an increased serotonergic state in the patho-
physiology of CFS.
Abbreviations
5-HT, 5-hydroxytryptamine; ATD, Acute tryptophan depletion; 
CFS, Chronic fatigue syndrome; SCID-1, Structured clinical interview for DSM-IV.
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Introduction
Chronic fatigue syndrome (CFS) is a medically unexplained syndrome, characterized 
by severe disabling fatigue for a period of at least 6 months that has led to 
considerable impairment in daily functioning1. Various accompanying symptoms 
may be present, such as headache, joint and muscle pain, sore throat, and 
impaired memory and concentration. Of the many therapeutic interventions that 
have been undertaken, so far only cognitive behavioral therapy and graded 
exercise therapy have met with success2.
Neuroendocrinological investigations have tried to elucidate the pathophysiology 
of CFS3. As CFS patients and adult patients with a growth hormone (GH) deficiency 
report similar symptoms such as fatigue, myalgia, a diminished sense of 
well-being, and reduced physical capacity4,5 and treatment of GH-deficient adults 
with GH has measurable effects on physical function and perception of fatigue6, 
GH status is a focus of this research. Changes in the GH/ insulin-like growth factor 
(IGF) 1 axis have been reported in CFS and fatigue-related disorders such as 
fibromyalgia7. 
 IGF1 studies in CFS patients have yielded conflicting results: low8,9, normal10,11, 
and increased12 basal IGF1 levels have been found. Sample size, selection of controls, 
appropriateness of matching, and selection of CFS patients with psychiatric 
co-morbidity could explain the conflicting results.
Despite the conflicting publications concerning IGF1 status in CFS patients, in 
recent years there have been reports in patient organization newsletters that a 
new food supplement called Acclydine could be an effective treatment for CFS. 
The active ingredient of Acclydine is an alkaloid from Solanum dulcamara. It has 
been claimed that Acclydine is effective because it increases IGF1 concentrations 
in CFS patients by stimulating GH releasing hormone and, consequently, GH 
secretion. GH is converted to IGF1 in the liver. IGF1 activates tyrosine kinase and 
integrin receptors and stimulates intra-cellular lipid and glycogen synthesis.
Levels of IGF binding proteins (IGFBPs), particularly IGFBP3, modulate the 
biological activity of IGF1, and the ratio of IGFBP3 to IGF1 reflects IGF1 biological 
activity13. There are unpublished observations suggesting that Accly-dine could 
increase the IGF1 plasma concentrations in healthy humans and in CFS 
patients. An 8-wk controlled trial with Acclydine in combination with amino acid 
supplementation in 90 CFS patients has been reported to have a positive effect14.
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However, there are, to our knowledge, no published peer-reviewed studies 
investigating the effect of Acclydine. Double-blind randomized controlled trials 
are needed, for several reasons. First, this food supplement is available on the 
Internet without prescription and is thus easily accessible. Second, although the 
effects of Acclydine treatment have not been evaluated thoroughly, there are 
ongoing studies in other vulnerable patient categories, such as in cancer patients 
with chronic fatigue after treatment, but these studies are not listed in the international 
controlled trial registry Current Controlled Trials (http://www.controlled- trials.com).
For the reasons given above, we assessed the IGFBP3/IGF1 status in patients 
fulfilling the US Centers for Disease Control and Prevention (CDC) criteria for 
CFS1 and in healthy gender- and age-matched neighborhood controls, to evaluate 
whether there are intrinsic differences in IGFBP3/IGF1 status between the two 
groups. Furthermore, we investigated the effect of Acclydine on IGF1 concentration, 
IGFBP3/IGF1 ratio, and CFS-related symptoms in a well-defined CFS population 
using validated outcome measures and a random-ized double-blind placebo- 
controlled design.
Methods
The study was approved by the medical ethical committee of the Radboud 
University Nijmegen Medical Centre. Written informed consent was obtained from 
all participants prior to enrollment.
Participants
Patients were recruited through the outpatient clinic of the Department of General 
Internal Medicine of the Radboud University Nijmegen Medical Centre and 
through an advertisement in the newsletter of the Dutch CFS patient organization 
 ME-Stichting (http://www.me-cvs-stichting.nl). Patients were eligible for 
participation if they fulfilled the following inclusion criteria: they had to be between 
18 and 65 y of age, and they had to fulfill the CDC consensus criteria for CFS1. 
A Structured Clinical Interview for DSM-IV (SCID-1) was performed to exclude 
patients with current psychiatric co-morbidity and to ensure a homogeneous 
group of patients.
Pregnant or lactating women were excluded, as were patients with lactose 
intolerance and patients taking psycho-tropic drugs or experimental medications.
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An additional criterion to be met was an IGFBP3/IGF1 ratio greater than 2.5. 
We asked patients who could potentially participate in the trial, if possible, to 
bring a healthy neighborhood control individual of similar age, gender, body 
weight, and body height, to compare IGF status. Except for contraceptives, the 
control individuals were not allowed to take medication.
Interventions
Acclydine and an identical placebo were delivered by the manufacturer 
Optipharma. Each Acclydine capsule contained 250 mg of the alkaloid. Patients 
took a single daily dose on an empty stomach, with the following decreasing 
Acclydine dosage schedule over a total of 14 wk: weeks 1–2, 1,000 mg per day; 
weeks 3–6, 750 mg per day; weeks 7–8, 500 mg per day; weeks 9–10, 500 mg 
every 2 d; weeks 11–12, 250 mg per day; and weeks 13–14, 250 mg every 2 d.
Acclydine treatment was combined with amino acid supplements to provide 
sufficient essential and nonessential amino acid intake during treatment. Patients in 
the placebo group received placebo Acclydine and placebo amino acid supplements.
There was no difference in taste, appearance, or packaging between the active 
supplements and the placebo capsules.
Design and Procedures
The study was a prospective, randomized, double-blind, placebo-controlled trial. 
The effect of Acclydine was assessed by pre- and post-trial testing. Post-trial 
testing was performed at the end of the 14-wk treatment period. During the 
post-trial assessments, the patients were still taking the trial supplements. All 
participants, investigators, and laboratory technicians were blinded to the 
treatment condition. IGF1 and IGFBP3 measurements were also done in a blinded 
fashion.
Randomization
Before the start of the clinical trial, the pharmacy of the hospital prepared 57 
treatment packages. Randomization and allocation to the treatment or placebo 
group was based on a patient’s study number. After acceptance of a patient by 
the junior researcher (G. K. H. T.) and the clinical psychologist (G. B.), the eligible 
patient received the lowest study number available (1–57). The pharmacy held the 
randomization list that correlated the study number with the treatment group. 
 To maintain balance over time, the concealed randomization was done in 
blocks of ten. Treatments were generated randomly within the blocks using a 
computer program (Excel, Microsoft, http://www.microsoft.com).
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Primary Outcome Measures
Fatigue severity
The Checklist Individual Strength is a reliable and validated self-report questionnaire. 
We used the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue)15,16. 
The score on this eight-item scale ranges from eight (no fatigue) to 56 (maximally 
fatigued). The cut-off point was set at 3517.
Functional impairment
The Sickness Impact Profile-8 (SIP-8) measures the influence of symptoms on 
daily functioning, using the following eight subscales to rate both physical and 
psychological disability: home management, mobility, alertness behavior, sleep/
rest, ambulation, social interactions, work, and recreation and pastimes18,19. CFS 
patients with substantial functional impairments were included. Patients with 
scores above the cut-off point of 800 were included.
Secondary Outcome Measures
Activity level
Besides self-reported outcome measures, we measured physical activity with an 
actometer. An actometer is a small motion-sensing device attached to the ankle; 
it was worn continuously for 14 d during the assessment periods. After the 2-wk 
period, the average score over 12 d was computed20. 
Daily fatigue level
During the 2-wk actometer period, patients rated their fatigue level in a complaint 
diary. They rated their level of fatigue four times a day on a zero (no fatigue) to four 
(maximally fatigued) scale. The four scores for each day were summed to produce 
the daily observed fatigue (DOF) score, which ranged from 0 to 1621. The mean of 
12 consecutive DOF scores was used.
Blood Samples
Blood samples of the patients and the matched neighborhood controls were 
taken at the same time, and the paired blinded samples were handled in an 
identical fashion. Serum IGF1 was measured by an immune radiometric assay 
(Diagnostic Systems Laboratories, http://www.dslabs.com). 
 For IGF1, the inter- and intra-assay coefficients of variation were 6.25% and 
4.93%, respectively. IGFBP3 was also assessed by an immune radiometric assay 
(Immulite, DPC, http://dpcweb. com). For IGFBP3, the inter- and intra-assay 
coefficients of variation were 4.25% and 1.3%, respectively.
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Statistical Methods
For all analyses SPSS 12.01 (SPSS, http://www.spss.com) was used.
 Power calculations before the start of the trial showed that 22 persons were 
needed in each group to detect a difference of at least one standard deviation 
(SD) on the CIS-fatigue with a power of 90% and a two-tailed significance level of 5%. 
Anticipating a dropout rate of 10%, at least 49 persons needed to be recruited. 
Analyses were performed on an intention-to-treat basis.
 Missing values were replaced by way of the last observation carried forward. 
Independent sample t-tests were performed on the change scores, defined as the 
difference between baseline scores and the post-treatment scores after 14 wk. 
IGF data are given as mean ± SD. The hormonal measurements were analyzed 
by independent sample t-test.
Results
All patients were recruited between February 2003 and April 2005. In total, 22 patients 
were able to bring a neighborhood control individual (four men and 18 women). 
The results of the hormonal assessments are shown in Table 1. Hormonal values 
including the CFS patients of the outpatient clinic and patients who did not meet 
the hormonal inclusion criteria for participation in the clinical trial are reported. 
No significant differences were found in the IGF status of the CFS patients versus 
the controls.
Figure 1 illustrates participant flow through the trial. In total, 112 patients were 
given information about the study protocol; 31 persons refused to participate, and 
the main reason given for refusal was the intensity of the study. Data obtained 
from 26 of the 31 persons who chose not to participate showed no significant 
Table 1  Hormonal Blood Levels
Hormone Patients (n = 22) Controls (n = 22) p-Value 
(95% CI)Mean (SD) Range (nm/l) Mean (SD) Range (nm/l)
IGF1 (nm/l)  37.0 (19.7) 18.6-96.1  36.9 (14.1) 18.6-76.1 0.98 
(-10.3 to 10.6)
IGFBP3 (nm/l)  117.6 (60.1) 51.1-224.7  114.5 (54.7) 56.0-240.8 0.86 
(-31.8 to 38.1)
Ratio IGFBP3/
IGF1
 3.7 (2.3) 0.89-9.24  3.5 (2.3) 1.37-9.84 0.82 
(-1.2 to 1.5)
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difference in age, number of CDC symptoms, fatigue severity, or functional 
impairment between the CFS patients participating in the clinical trial and those 
who chose not to participate (data not shown). Twenty-four patients did not meet 
the inclusion criteria. A total of 57 patients were randomized in the clinical trial: 15 
patients were recruited from the outpatient clinic, and 42 patients came in 
response to the advertisement in the patient organization newsletter. One patient 
in each arm dropped out after randomization, and as a consequence, in each 
arm, baseline data for one patient was carried forward, and a sensitivity analysis 
was not required. 
Figure 1   CONSORT Flowchart.
Reasons:
Burdon  (n = 18)
Starting other therapy (4)
Research with placebo (3)
Acclydine not feasible in CFS treatment (3)
Unknown reason (3)
Reasons:
IGFBP3/IGF1 ratio < 2.5 (8)
Psychiatric co-morbidity (4)
Not fulfilling fatique or impairment criteria (4)
Not fulfilling the CDC criteria (4)
No CFS diagnosis (3)
Pregnancy (1)
Assessed for eligibility (n = 112)
Refusal n = 31
Not eligible n = 24 
Placebo (n = 27)
Completers (n = 26)
Supplement (n = 30)
Completers (n = 29)
Randomization (n = 57) 
AssignedAssigned
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The Acclydine and placebo treatments were well tolerated. No important side 
effects were reported in either group. The Acclydine and placebo groups did not 
differ with respect to age, gender, fatigue severity, impairment, or number of CDC 
symptoms (Table 2).
Primary Outcomes
No significant differences in change scores were found between the treatment 
and placebo groups on the primary outcome measures (Table 3). The CFS 
patients treated with Acclydine did not show a significant decrease in fatigue 
severity (CIS-fatigue +1.1 [95% CI -4.4 to +6.5, p=0.70]) or functional impairment 
(SIP-8 +59.1 [95% CI -201.7 to +319.8, p=0.65]) compared to the placebo group.
Secondary Outcomes
Actometer activity scores did not show significant differences between the two 
groups. Analysis of fatigue severity rated with the DOF did not show significant 
differences either.
No significant differences were found between the treat-ment and placebo groups 
in IGF1 blood level, IBFBP3 blood level, or IGFBP3/IGF1 ratio at baseline; after 4, 
8, or 14 wk of treatment; or during follow-up (Figure 2).
Table 2  Patient Characteristics
Charateristic Accydine Group (n = 30) Placebo Group (n = 27)
Age, years  40.9 (9.4)  43.4 (11.2)
Female 77% 59%
CIS-fatigue  46.5 (7.4)  46.2 (7.9)
SIP-8  1,484 (520.4)  1,317 (481.7)
CDC symptoms  7.6 (1.4)  7.5 (1.3)
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Figure 2   Hormone Data of the Two Treatment Groups.
(A) IGF-1 concentration, mean (sd)
(B) IGF-BP3 concentration, mean (sd)
Accydine (n = 30)
Placebo (n = 27)
(C) Ratio IGF-BP3 / IGF-1, mean (sd)
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Discussion
Interpretation
In this randomized controlled blinded clinical trial, no therapeutic effect of 
Acclydine in CFS was found. In this study we also addressed the issue of a 
deficiency of bioactive IGF1. To control for unwanted stress effects and other 
confounders, the blood samples were taken simultaneously from the patients and 
their matched neighborhood controls. For each pair of patient and control, the 
measurements of IGF1 and IGFBP3 were performed in the same run. 
 In addition, we detected no differences in IGF1 or IGFBP3 concentrations in 
CFS patients without psychiatric co-morbidity versus closely matched healthy 
neighborhood controls. Although the sample size is relatively small, the results do 
not point to a different IGFBP3/IGF1 status in CFS patients compared to controls. 
These results do not support the hypothesis that changes in IGF1 and IGFBP3 
metabolism are involved in the pathophysiology of CFS.
Generalizability
In this study we enrolled a representative sample of adult referred and non-referred 
CFS patients who fulfilled the international CDC consensus criteria for CFS1. 
In contrast to previous intervention studies with cognitive behavioral therapy22 or 
with a polynutrient supplement23 conducted by our research group, we excluded 
patients with psychiatric co-morbidity to exclude hormonal influences caused 
by current psychiatric co-morbidity. The mean fatigue severity and functional 
impairment scores in this study represent high fatigue severity levels and high 
functional impairment in the CFS patients. Compared to the previously mentioned 
intervention studies, the patients in this clinical trial reported slightly lower fatigue 
and functional impairment scores. Selection of CFS patients without current 
psychiatric co-morbidity could explain this difference.
Overall Evidence
To our knowledge, this is the first published report of a randomized controlled trial 
evaluating the effect of the food supplement Acclydine in CFS patients. The effect 
was assessed by pre- and post-trial testing with validated instruments designed 
to assess different dimensions of CFS as well as treatment effects. Treatment with 
Acclydine was not more effective than placebo in changing self-reported outcome 
measures, hormonal blood levels, or physical activity.
The lack of significant differences on any of the dimensions of fatigue or the 
hormonal assessments strengthens our overall findings.
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Previous unpublished studies by others on file at the manufacturer claimed that 
treatment with Acclydine would be more effective in CFS patients with a higher 
IGFBP3/IGF1 ratio. Based on this claim, we did a subset analysis for patients with 
a ratio greater than 4.5:19 CFS patients in the Acclydine group and 20 in the 
placebo group had a ratio greater than 4.5. No significant differences in change 
scores were seen between the subgroups in any of the outcome measures.
A second claim was that Acclydine treatment works by increasing biologically 
active IGF1. However, assessment of IGF1 concentration and IGFBP3/IGF1 values 
in the Acclydine group at baseline, 4 wk, and 8 wk during treatment, at the end of 
treatment, and at follow-up (1 mo after the treatment period) did not show a 
significant change.
The power of our study was sufficient to detect changes in time in both groups. 
Thus, the negative findings found in this randomized controlled trial cannot be 
explained by a power problem. Considering the reported treatment effect on the 
primary outcome measures, we believe it is very unlikely that a larger trial would 
detect a clinically meaningful effect.
It is of interest to note that we detected a minor placebo effect in this study. This 
is in accordance with observations from earlier randomized controlled clinical 
trials in CFS23,24,25. However, the minimal decline in fatigue severity and functional 
impairment during pre- and post-trial testing in both treatment groups could also 
be partly explained by the phenomenon regression to the mean or a Hawthorne 
effect.
We did not monitor patient compliance on a daily basis. During the trial, patients 
had an appointment by telephone or at the outpatient clinic every 2 wk. During 
these appointments, we assessed whether the capsules were taken as directed, 
and the treatment protocol for the next 2 wk was discussed with the patient. 
Although adherence could not be verified fully, there is no reason to believe that 
lack of adherence can explain the negative findings.
In conclusion, this randomized controlled trial did not demonstrate an effect of 
Acclydine on biologically active IGF1, nor did it demonstrate any benefit in CFS- 
related outcome measures. Thus, the findings of this clinical trial do not support 
the use of Acclydine in the treatment for CFS.
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We feel that the negative results of this trial are important for two reasons: 
Acclydine is expensive, so patients might be spending a lot of money on an 
ineffective treatment, and it is also available without prescription on the Internet, 
making it available to patients potentially without a doctor’s oversight.
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GENERAL DISCUSSION
In this thesis, I have presented the results of four studies in chronic fatigue 
syndrome. These trials were performed to seek evidence for disturbances in 
Insulin-like Growth Factor and in the serotonin metabolism. In this final chapter, 
I will summarise the results of these studies, place them into perspective of 
the existing CFS literature, and discuss scientific and clinical implications. I will 
furthermore provide suggestions for future research.
Insulin-like Growth Factor 
Regarding a potential role of Insulin-like growth factor (IGF), two hypotheses were 
tested. The first hypothesis was that basal IGF concentrations are low in CFS. To 
that end, basal IGF concentrations in adult CFS patients were compared with 
those in matched neighbourhood controls. The second hypothesis tested was 
that Acclydine, a food supplement, is an effective treatment in CFS. This was in 
accordance with a claim of the manufacturer of this compound and the assumption 
that it would enhance IGF concentrations. A randomised placebo-controlled trial 
was performed to assess the efficacy of Acclydine treatment during 14 weeks.
 First of all, there was no difference in basal serum IGF-1 and IGF-BP3 levels 
between the CFS patients and age and gender-matched neighbourhood controls. 
With regard to the second hypothesis, treatment with Acclydine was ineffective in 
CFS. No differences between the treatment and placebo groups were found in 
any of the outcome measures. In addition, Acclydine did not alter IGF metabolism 
in the treatment group. 
The Acclydine RCT was published in 2007. Until 2007, Acclydine was promoted 
and sold on the internet. In addition, an unpublished study from Belgium was 
presented at the Australian CFS/ME Conference in 2001, claiming a significant 
increase in IGF-1 levels in CFS patients and a significant improvement in CFS 
symptoms. The fact that many patients and insurance companies asked our 
opinion prompted us to carry out this investigation. No studies have been 
published investigating the effect of Acclydine after 2007. In our opinion, further 
Acclydine research is not needed and an expensive Acclydine treatment is not 
warranted. 
 CFS studies investigating insulin-like growth factor status were mainly 
published between 1996 and 2005. A more recent cross sectional study found no 
statistically significant changes of IGF in chronic fatigue, chronic widespread 
pain, irritable bowel syndrome, and chronic orofacial pain1. There is no convincing 
evidence that IGF dysfunction plays a role in CFS2,3,4.
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The main reason for performing the Acclydine clinical trial was to assess its 
efficacy for the aforementioned reasons. The trial was not designed to thoroughly 
investigate the insulin-like growth factor axis, and focusing on one pathway 
obviously has its limitations as neuroendocrine pathways and neurotransmitter 
systems interact in a complex manner. The search for a single cause or one 
specific disruption in a specific neuroendocrine system or one neurotransmitter 
system in CFS has not led to a specific explanation of CFS symptoms. 
Serotonin
We performed three intervention studies to pursue the question on whether 
serotonin metabolism is upregulated in CFS. Although our first open label pilot 
study with the 5-HT3 receptor antagonist granisetron met with promising results 
(chapter 2), no therapeutic benefits were found in the larger placebo-controlled 
double-blind study using ondansetron (chapter 3). In this study we used 
ondansetron, another 5-HT3 receptor antagonist because we could not obtain 
granisetron after the merger of two large pharmaceutical companies. The 
differences between granisetron and ondansetron are discussed in more detail 
below. 
In a next study (reported in chapter 4), the effect of acute tryptophan depletion 
was assessed in a placebo-controlled design. We can conclude that all three 
serotonin interventions performed had negative results. 
 Though results regarding the efficacy of selective serotonin reuptake Inhibitors 
(SSRI’s) in CFS are mixed5, our Nijmegen group previously found in a randomised 
placebo controlled double-blind study that the SSRI fluoxetine is ineffective in 
CFS patients with depression and without depression6. Blocking serotonin with 
ondansetron and lowering brain serotonin levels with acute tryptophan depletion 
are therefore ineffective in CFS treatment.
How can these negative results be explained? 
A negative clinical trial may be due to lack of a pharmacological effect, though 
other possibilities should also be taken into account.
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Ondansetron clinical trial
Could pharmacological differences between granisetron and ondansetron be an 
explanation for the difference in effect between granisetron and ondansetron? 
Pharmacodynamics
Ondansetron has proven anti-emetic properties and is used in chemotherapy and 
postoperative induced nausea and vomiting7. Many studies of ondansetron have 
been published since its introduction in the early Nineties. 
 The vomiting reflex after chemotherapy is probably caused by a chemo-
therapy-induced increase of serotonin release. Chemotherapy-induced increase 
of serotonin is treated with serotonin-blocking agents like ondansetron. 
 There is a parallel with our hypothesis of an increased serotonin metabolism 
in CFS and investigating the effect of serotonin antagonism. Ondansetron is 
effective by blocking serotonin receptors from the enterochromaffin cells and by 
blocking serotonin at the level of the central nervous system8. Ondansetron is 
considered the prototypical drug in the class of 5-HT3 receptor antagonists. 
Differences among the 5-HT3 antagonists are mainly attributed to chemical 
structures, pharmacokinetics and binding properties9. The binding potential of 
several 5-HT3-receptor antagonists has been evaluated in radioligand binding 
studies in animals10. The affinity of granisetron and ondansetron for the 5-HT3 
receptor in rats are >600 and 184 times that of serotonin. 
 Both antagonists are highly effective in competing with serotonin for the 
5-HT3 receptor11. Although both are considered effective 5-HT3 antagonists, they 
may differ in their binding potential to centrally located 5-HT3 receptors. 
 For example, preclinical pharmacodynamic studies have shown that 
granisetron exhibits little or no binding to centrally located 5-HT3 receptors12,13. 
So this would not explain the observed difference in effect in CFS of the two 
drugs. However, there is evidence that receptor blockade produced by 
ondansetron is much shorter than that produced by granisetron14, and there are 
observations that ondansetron penetrates the blood-brain barrier slowly15. 
Although we used an equipotent dosage of ondansetron compared to 2 mg 
granisetron used in the pilot study, it is not fully clear if binding profile differences 
explain the lack of an ondansetron effect. 
Pharmacogenetics
It has in recent years been recognised that genetic polymorphisms contribute to 
drug responsiveness. The science of pharmacogenetics is developing and 
differences in the genetic makeup of the CFS patient participating in our clinical 
trial could influence the response to ondansetron. Potential factors influencing 
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response include polymorphisms associated with drug transport, the serotonin 
receptor and drug metabolism via cytochromes P450.
Transporter polymorphism
Drug transporters play a key role in the passage of drugs across the blood brain 
barrier, thus determining the disposition of drugs and the drug concentration in 
the central nervous system. The transporter adenosine triphosphate-binding 
cassette subfamily B member 1 (ABCB1) has been identified in playing an 
important role in the ondansetron pharmacokinetics16. The ABCB1 transporter 
functions as an efflux pump17 and its highly polymorphic and genetic variance 
could influence the efficacy of Ondansetron. For example, Chio et al. found a 
strong association between the polymorphisms (2677G>T/A) and 3435C>T/A of 
the ABCB1 transporter and the response to ondansetron in post-operative nausea 
and vomiting patients. 
 Patients were treated with ondansetron and the incidence of postoperative 
nausea and vomiting was lower in patients with the 2677G>T/A and 3435C>T/A 
polymorphism18 . Patients with homozygous 2677TT and 3435TT genotypes 
responded better to ondansetron treatment. The authors hypothesise that it is 
likely that a higher concentration of ondansetron in the central nervous system 
due to the ABCB1 polymorphisms and a reduced transporter activity could 
explain a better efficacy of ondansetron. The two polymorphisms have shown a 
high inter-ethnic variability. It is estimated that approximately 25% of the Caucasian 
population19,20 are homozygous carriers of 3435TT polymorphism and 16% of the 
Caucasian population are homozygous carriers of 2677TT polymorphism21. Many 
single-nucleotide polymorphisms in the ABCB1 transporter have been identified 
and the clinical relevance should be further established22. Since these 
polymorphisms are found in a substantial percentage of Caucasians, it cannot be 
ruled out, given the sample size of our trial (n=67), that transporter polymorphisms 
could explain the negative findings. 
5-HT3 receptor polymorphism
The 5-HT3 receptor is a ligand-gated ion channel. Until now five different 5-HT3 
receptor subunits (HT3A - HT3E) have been identified. 
 Ondansetron specifically binds to the 5-HT3A and 5-HT3B receptor complex. 
The 5-HT3B subunit has shown to be the most important for its functionality23. 
Tremblay et al. found that cancer patients who were homozygous for the 
100_-102AAG deletion polymorphism of the 5-HT3 gene were associated with a 
higher incidence of chemotherapy-induced nausea and vomiting in cancer 
patients24. However, Rueffert et al. could not confirm this specific result in patients 
with post-operative nausea and vomiting25. In 2015, Kim and colleagues found the
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 -100_-102AAG deletion polymorphisms of the 5-HT3b gene to be associated with 
a higher incidence of post operative nausea and vomiting and with ondansetron 
responsiveness26.
 There is still limited data on the 5-HT3B gene frequency status and allele 
frequency in different populations. Further research is necessary to assess the 
relationship between the genotype of the 5-HT3 receptor and drug response to 
5-HT3 receptor antagonists. Research in the treatment of post-operative nausea 
and vomiting with 5-HT3 antagonists demonstrates that we should consider the 
possible influence of polymorphisms of the 5-HT3 receptor.
Pharmacokinetics
Different studies point out that, unlike the other 5-HT3 receptor antagonist, 
granisetron’s principal route of metabolism is mediated by P450 CYP3A4 
isoenzyme27,28. Granisetron metabolism does not rely on CYP2D629. Ondansetron 
is also metabolised by the cytochrome P450 CYP2D6 and is subject to potential 
genetic polymorphisms9. Candiotti et al. found Ondansetron to be less effective 
in ultra rapid metabolisers in postoperative vomiting30. In a more recent study, 
Trammel et al. report less efficacy of ondansetron in acute chemotherapy- induced 
and vomiting in ultra rapid metabolisers29.
 The frequency of ultra rapid metabolisers differs widely among ethnic groups. 
Bernard et al. report high frequencies of ultra rapid metabolisers in Saudi Arabian 
patients (21%), Ethiopian (29%), Spanish (10%) and Turkish patients (8.7%). Ultra 
rapid metabolisers are present in less than 5% in Caucasians31. 
 In our clinical trial, CYP2D6 polymorphism could be another factor to consider 
when reflecting on the negative results found in our randomised clinical trial. 
Although we did not specifically check the ethnicity in our randomised clinical 
trial, the patients were mainly Caucasians and it is highly unlikely that differences 
in 2D6 metabolism could explain the negative results in the ondansetron trial. In 
conclusion, the study design of our ondansetron clinical trial did not take into 
account genetic polymorphisms. This factor should be included in the future trial 
designs.
Could non-adherence be an explanation?
Patients were asked in the RCT if the medication had been taken consequently 
every two weeks. Our publication states that we do not believe that lack of 
adherence can explain the negative findings. Regular assessment of ondansetron 
blood concentration levels would be the appropriate method for checking 
compliance, but this would have increased both the burden for already 
incapacitated patients and the investigator-initiated trial costs.
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 We noted that the CFS-patients participating in the burdensome clinical trial 
were highly motivated, and the very low withdrawal rate in the clinical trial (3 out 
of 33 patients in the ondansetron group and no withdrawal in the placebo group) 
could be a reflection of this high motivation and good compliance. 
Is the placebo response similar to that in other CFS trials?
The ondansetron trial is a study oriented towards a somatic (‘biological’) disease 
mechanism. CFS patients have somatic attributions and somatic attributions are 
considered to be perpetuating factors32. Such a somatically-oriented study would 
meet with less scepticism and perhaps with higher expectations, beliefs of a 
positive result and high motivation in the CFS patients participating in the trial. 
These factors could influence the placebo effect. Cho et al. investigated the 
placebo effect in CFS. The placebo response, which was defined as the proportion 
of responders in a placebo arm, was investigated. The authors found a low (19.6%) 
pooled placebo response in CFS. Psychological-psychiatric interventions were 
shown to have the lowest placebo response (14%) and interventions based on the 
assumption of physical causality (infectious or immunological) were shown to 
have the highest placebo response (24%)33. In the placebo group in our study, we 
found a placebo response of 23%. Eight out of the 34 patients in the placebo 
group showed a significant improvement in fatigue severity. Thus the placebo 
response in our ondansetron clinical trial seems similar to placebo response 
found in the literature for studies directed towards physical disease mechanisms.
Could strict inclusion criteria have reduced the likelihood of achieving 
response to ondansetron? 
A sizeable percentage of CFS patients have current psychiatric co-morbidity. The 
presence of current psychiatric disorders was an important exclusion criterion in 
our clinical trial. High fatigue severity scores and high impairment levels were also 
part of the inclusion criteria, and patients had to be able to visit the research 
facility. It is important to take into account, when there are too many inclusion and 
exclusion criteria or if the criteria are too strict, the risk that patients participating 
in a trial are not representative of the patients seen in clinical practice, and the 
sample could be considered as a select sample with a low external validity.
 The characteristics of the population enrolled in our trial did not differ from 
other studies of groups of CFS patients studied in our centre: age, gender, fatigue 
severity and CDC symptoms were similar34,35,36. 
 No other trials have been published investigating the effect of serotonin-blocking 
strategies after the ondansetron publication in 2010. Performing analysis based 
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on pooled data and larger sample sizes is therefore still not possible. Despite our 
study’s limitations, we will assume that the absence of an effect in the larger 
ondansetron trial reflects a lack of a pathophysiological role of serotonin in CFS.
Tryptophan Depletion
Acute tryptophan depletion was not effective in the treatment of CFS. Acute 
tryptophan depletion is an accepted method to lower central serotonin levels. The 
pilot study was performed in five CFS patients. A major concern is the lack of 
power in our study and larger trials are required to assess the effect more 
thoroughly. 
Could heterogeneity at the serotonin level explain the negative findings?
Badawy et al. reported that two subgroups of CFS patients could be identified 
based on their serotonin status. They proposed criteria for defining a high 
serotonin status. Free serum tryptophan, total serum tryptophan and the ratios 
(free serum tryptophan/BCAA and total serum tryptophan/BCAA) should lie 
outside the 2 SD range37. We compared the total tryptophan/BCAA ratios of the 5 
CFS patients participating in our ATD study with the ratios of 5 healthy female 
controls of the same age from the same laboratory. The ratios of the CFS patients 
and the healthy controls were similar. We found no evidence for a high serotonin 
status in the CFS patients. 
 One could hypothesise that acute tryptophan depletion or treatment with 
serotonin antagonism could only be effective in CFS patients with a high serotonin 
status.
 We did not find evidence for an increased serotonin status in CFS patients in 
this study. Our conclusion was based on a small intervention study only and what 
can be concluded is that the negative results did not yield much hope of more 
extensive studies greatly changing our insight. But an integrated approach 
investigating serotonin metabolism in CFS may certainly yield more fundamental 
insight into serotonin status in CFS. Besides peripheral assessment of serotonin 
status with blood serum and urine measurements, serotonin status could also be 
determined with central parameters. Use of positron emission tomography (PET) 
and single photon emission computed tomography (SPECT) with 5-HT-specific 
radioligands will allow to eventual 5-HT(1A) and 5-HT(2A) receptor and 5-HT 
transporter alterations in CSF. In this way, correlations between central and 
peripheral outcome measures, as well as changes after CBT could be investigated. 
As previously stated, we did not have high expectations from such studies, and it 
is uncertain if more insight in the serotonin status will lead to clinical relevant 
findings for treatment. More importantly, funding for these studies was not 
Processed on: 3-10-2016
505445-L-bw-The
94
CHAPTER 6
available. Based on the intervention studies presented in this thesis, I do not think 
that further exploration of the serotonin status in CFS should have a high priority. 
New developments
Definitions of chronic fatigue syndrome
The studies presented in this thesis were published between 2003 and 2014. 
Other important recommendations and guidelines have been published since 
2003. In 2007, the CFS NICE clinical guideline was published38. The CFS report of 
the Health Council of the Netherlands was published in 200539, and the 
development of a Dutch CFS guideline was recommended. In 2013 the Dutch 
CFS guideline was published40. All publications emphasise the necessity of 
further scientific research. The international case definition (CDC 1994 criteria), 
which was primarily formulated for research purposes, is still considered to be the 
standard, and we applied this in all our studies41,42 (Fukuda 1994, Reeves 2003).
 Another definition has recently been proposed. The prestigious Institute of 
Medicine in the United States established a committee on CFS in 2015. This 
committee released its report ‘Beyond Myalgic Encephalomyelitis/ Chronic 
Fatigue Syndrome: Redefining an Illness’. The committee proposes to change the 
name Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome to Systemic 
Exertion Intolerance Disease (SEID). In this definition, the core feature of the 
disorder is post-exertional malaise instead of persistent or relapsing unexplained 
chronic fatigue in the 1994 case definition. 
The scientific community has received this proposal with astonishment and 
disagreement. Most scientists and doctors agree that the name Myalgic Enceph-
alomyelitis is a misnomer, but there is little reason to change a name when there 
is not a profound change in the understanding of the pathophysiology of the 
disorder. Secondly, to change from ‘syndrome’ to ‘disease’ also suggests that 
it concerns a homogeneous disease entity and that we understand the patho-
physiology. 
A third reason regards the proposed name of Systemic Exertion Intolerance 
Disease. Systemic suggests that we know it is a systemic disorder. The evidence 
for this is virtually absent. Most data point to the brain as the site of the substrate, 
and all other symptoms can been seen as secondary to that. Using ‘exertion 
intolerance’ in the name cannot be seen as an improvement. The fatigue and the 
accompanying symptoms are not a result of exertion: patients wake up fatigued, 
sleep does not refresh; exercise and exertion are not critical for the symptomatology. 
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Finally, the diagnostic criteria lack a sound scientific basis. Sensitivity and 
specificity are not taken into account. Though the 3 mandatory symptoms are 
reasonable, but – like in the CDC criteria – no effort has been undertaken to try 
and quantify the degree of impairment. The choice of the two ‘minor’ manifestations, 
i.e., cognitive impairment and orthostatic intolerance also gives rise to concern. 
Cognitive impairment in CFS most often cannot be substantiated. 
Orthostatic intolerance is also relatively rare, as became apparent in three studies 
from our group43,44. 
Future research priorities 
It is clear that the IOM report is not a good starting point for further research. So 
which research priorities do I envisage? 
 In this respect, it is of interest that the National Institute of Mental Health 
(NIMH) recently updated its strategic plan and defined research priorities and 
launched the Research Domain Criteria Initiative (RDoC)45 (see https://www.nimh.
nih.gov/research-priorities/rdoc/index.shtml). 
 Two objectives may be relevant for future CFS research. Firstly, based on the 
understanding of brain disorders, the NIMH states that mental illnesses are the 
late signs of changes in brain circuits. A more refined understanding of underlying 
mechanisms of perception, cognition and motivation is essential. 
 The answers will come from hypothesis testing and discovery-based studies 
examining the biological mechanisms underlying symptoms and mental processes. 
Next, the NIMH states that the best time to address a mental illness is before the 
appearance of symptoms that disrupt daily life. Research will be supported to 
develop biomarkers and assessment tools to predict illness onset, course and 
intervention response. Critical questions furthermore include how biological 
mechanisms are linked with environmental factors such as stress and experience 
such as trauma (NIMH strategic plan)46,47. 
 One can conclude that, in line with NIMH mental health research priorities, 
the challenge in CFS research is investigating biological, psychological and 
environmental factors in a multidisciplinary and integrated approach. To study 
CFS in an early stage is a relevant suggestion. This would mean to study patients 
within 6 months and 1 year of illness should be a research priority. The ambition 
to study CFS patients before symptoms appear is more difficult, given the rarity of 
CFS. Studies of this kind have been performed in patients with acute Epstein Barr 
virus infection48,49,50,51,52. 
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 Other infections that are regularly followed by CFS or symptoms that resemble 
CFS are Q fever and Lyme disease. Recently Keijmel et al. published the first 
study comparing CFS patients and Q fever fatigue syndrome (QFS) patients53. 
Investigating differences and similarities between CFS and QFS will yield a better 
understanding of the pathogenesis of chronic fatigue that may complicate Q fever 
infection.
As stated above, I would not prioritise further research on the role of serotonin in 
the pathogenesis of CFS. 
 The Nijmegen Expert Centre Chronic Fatigue is at present carrying out 
research on the potential role of the cytokine interleukin-1 by doing a controlled 
clinical trial with the specific inhibitor anakinra (Il-1 receptor antagonist). Such an 
intervention is based on the hypothesis that there is (low-grade) inflammation in 
the brain (Clinicaltrials.gov: registry: NCT02108210 and BMC clinical trials 
2015,16:439). 
Exploring the inflammatory hypothesis is definitely an important next step. 
Accumulating evidence from neuroimaging studies demonstrate neural abnormalities 
in CFS patients54. 
 Other studies currently undertaken deal with the structure and functioning of 
the brain, using MRI scanning. Patients with CFS were found to have reduced 
grey matter volumes that increased following treatment with CBT55. Furthermore, 
a randomised controlled trial has begun aiming to replicate these effects of CBT 
on grey matter volumes. Also the mechanisms that underlie the effects of CBT are 
investigated by means of task-dependent functional MRI and immune and 
endocrine biomarkers56. 
 These  studies are much needed and are, in my opinion, a good direction to 
choose.
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SUMMARY
Summary
The title of this thesis is: ‘Chronic Fatigue Syndrome; Targeting Serotonin and 
Insulin-like Growth Factor’. This dissertation reports on four studies, in which the 
role of serotonin and Insulin-like growth factor are investigated to elucidate the 
pathogenesis of chronic fatigue syndrome (CFS). 
Patients with CFS experience severe and medically unexplained chronic fatigue 
that results in tremendous impact on the lives of patients and their families.
Cognitive behavioural therapy (CBT) has proven to be a successful intervention 
leading to a reduction in fatigue and impairment. CBT can result in a full recovery. 
Unfortunately some patients do not profit from CBT and more insight into the 
neurobiology of CFS is highly necessary to improve our understanding of this 
illness.
Chapter 1
In the introduction the outline of this thesis is presented. The diagnostic criteria for 
CFS and the evaluation of chronic fatigue are described and the complex role of 
psychiatric disorders in CFS is discussed. 
 Furthermore the hypothesis of an upregulated serotonin system and the 
hypothesis of deficient insulin-like growth factor hormone in the pathophysiology 
of CFS are explained.
This thesis comprises three studies targeting serotonin and one study targeting 
insulin-like growth factor in the pathophysiology of chronic fatigue syndrome.
Chapter 2
The goal of chapter 2 was to investigate the therapeutic potential of the serotonin 
receptor antagonist granisetron in adult CFS-patients. This was the first CFS 
study investigating the hypothesis of an up-regulated serotonin system by means 
of serotonin antagonism. 
 A pilot study was performed in 5 CFS-patients, with low activity levels. The 
effect of 1 mg granisetron for two weeks and 2 mg for the second two weeks was 
evaluated. 
 Four out of the five patients reported significant improvement in fatigue severity 
and functional impairment. Treatment did not result in improved physical activity. 
We concluded that performing a randomised placebo-controlled clinical trial was 
warranted.
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Chapter 3 
In chapter 3, the results of a double-blind clinical trial are presented. We were 
interested if the positive results of the pilot study would be replicated in a clinical 
trial design. Sixty seven adult CFS patients were treated with the 5-HT3 receptor 
antagonist ondansetron, 16 mg per day. Patients were treated for a period of 10 
weeks with an equipotent dose of 2 mg granisetron. The primary outcome measures 
were fatigue severity and functional impairment. Secondary outcome measures 
were physical activity level and daily fatigue level. We did not find significant 
differences between the ondansetron- and placebo group in any of the outcome 
measures. The findings of this clinical trial do not support the use of 5-HT3 
receptor antagonism in the treatment of CFS.
Chapter 4
In chapter 4, serotonin metabolism in CFS was investigated further. In a small 
proof of principle study the effect of transient acute tryptophan depletion (ATD) 
was assessed. Serotonin metabolism was significant reduced by the paradigm 
ATD. The effect of ATD was assessed in a double-blind cross-over design. 
 We found no significant differences between the ATD- and the placebo group.
Further research with larger sample sizes is needed to allow a more definite answer. 
Chapter 5
In chapter 5, the hypothesis of a deficient insulin-like growth factor is elaborated.
The results of a randomised clinical trial with Acclydine, a food supplement, are 
presented. Acclydine was promoted as an effective treatment for CFS. Evidence 
for efficacy is lacking. We found no differences in insulin-like growth factor status 
in CFS-patients compared to healthy matched neighbourhood controls. 
 Treatment with Acclydine during 14 weeks was not effective and no differences 
were found between insulin-like growth factor status and CFS related symptoms 
between the Accyline- and the placebogroup.  
Chapter 6
Finally, in chapter 6 the findings of the four studies were discussed and were 
put into perspective. The 2015 proposed new definition of CFS by the Institute of 
Medicine is discussed and possible directions for future research were formulated.
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In dit proefschrift getiteld: ‘Chronic Fatigue Syndrome; Targeting Serotonin and 
Insulin-like Growth Factor’, worden de resultaten van 4 studies beschreven waarin 
de rol van serotonine en Insulin-like growth factor zijn onderzocht met als doel 
meer inzicht te verkrijgen in de pathogenese van het chronisch vermoeidheids-
syndroom (CVS).
 
CVS wordt gekenmerkt door ernstige aanhoudende vermoeidheid. Er is geen 
lichamelijke verklaring voor de vermoeidheid en CVS heeft grote gevolgen voor 
de patiënten en hun familie.  
Cognitieve gedragstherapie (CGT) is een effectieve behandeling die leidt tot een 
afname van de vermoeidheid en beperkingen. Volledig herstel van CVS na CGT is 
mogelijk, echter behandeling met CGT is niet bij alle patiënten succesvol. Meer 
kennis van de neurobiologie van CVS is nodig. 
Hoofdstuk 1
In de introductie wordt een algemene inleiding gegeven over CVS. De diagnostische 
criteria en uitgangspunten voor de analyse van patiënten met chronische 
 vermoeidheidsklachten en de complexe rol van psychiatrische stoornissen worden 
beschreven. 
 De hypotheses van een ‘overgevoelig serotonine systeem’ en een ‘deficient 
insulin-like growth factor hormoon’ systeem bij CVS worden uiteengezet. 
Dit proefschrift beschrijft drie studies die het serotonine systeem onderzoeken 
en een studie die zich richt op het insulin-like growth factor hormoon bij CVS- 
patiënten.
Hoofdstuk 2
Het doel van hoofdstuk 2 is het effect van granisetron, een serotonine receptor 
antagonist, te onderzoeken bij volwassen CVS-patiënten. Dit was het eerste CVS 
onderzoek dat de hypothese van een ‘overgevoelig serotonine systeem’ onder- 
zocht door middel van een medicamenteuze interventie met een serotonine 
antagonist.
 Een pilot onderzoek werd verricht bij 5 CVS-patiënten met een lager niveau van 
fysieke activiteiten. Het effect van 1 mg granisetron gedurende twee weken en 2 mg 
gedurende de opeenvolgende twee weken werd onderzocht. Vier van de vijf 
patiënten lieten een significante verbetering in de ernst van de vermoeidheid en in de 
ernst van beperkingen zien. Behandeling met granisetron leidde niet tot een 
Processed on: 3-10-2016
505445-L-bw-The
110
SAMENVATTING
verbetering van het fysieke activiteiten niveau. Gezien de positieve resultaten van 
de pilot studie werd besloten een gerandomiseerde dubbebblinde clinical trial 
uit te voeren.  
Hoofdstuk 3
In hoofdstuk 3 worden de resultaten van de dubbelblinde clinical trial beschreven. 
De vraag was of de positieve resultaten van de pilot studie gerepliceerd konden 
worden. Zevenenzestig volwassen CVS-patiënten werden behandeld met 16 mg 
ondansetron, een 5-HT3 receptor antagonist. De patiënten werden gedurende 
10 weken behandeld met een equipotente dosering van 2 mg granisetron.
 De primaire uitkomstmaten waren ernst van de vermoeidheid en beperkingen.
 De secundaire uitkomstmaten waren fysiek activiteiten niveau en dagelijks 
ervaren vermoeidheid. Er werd geen enkel significant verschil gevonden in alle 
uitkomstmaten tussen de ondansetron- en placebo groep. De resultaten geven geen 
onderbouwing CVS-patiënten te behandelen met een 5-HT3 receptor antagonist. 
Hoofdstuk 4
In hoofdstuk 4 wordt het serotonine systeem verder onderzocht.
 In een klein ‘proof of principle’ onderzoek werd het effect van Acute Tryptofaan 
Depletie (ATD) onderzocht. Door middel van ATD werd het serotonine niveau 
significant verlaagd. Door middel van dubbel-blind cross-over onderzoek werd 
het effect van ATD bekeken. Er werd geen significant verschil gevonden tussen de 
ATD- en placebo groep. Verder onderzoek met grotere aantallen is nodig om tot 
een meer definitief antwoord te komen.
Hoofdstuk 5
In hoofdstuk 5 wordt de ‘deficient insulin-like growth factor hormoon’ hypothese 
bij CVS toegelicht. De resultaten van een gerandomiseerd clinical trial met Acclydine, 
een voedingssupplement, worden beschreven. Acclydine werd gepromoot als een 
effectieve CVS-behandeling, hoewel hier geen wetenschappelijk bewijs voor was.
 Er werd geen verschil gevonden in insulin-like growth hormoon status tussen 
CVS-patiënten en gezonde gematchte buurtcontroles.
 Behandeling met Acclydine gedurende 14 weken bleek niet effectief. Er werden 
geen verschillen gevonden in insulin-like growth hormoon status en CVS gerelateerde 
uitkomstmaten tussen de Acclydine- en placebogroep.
Processed on: 3-10-2016
505445-L-bw-The
111
SAMENVATTING
Hoofdstuk 6
Ten slotte, in hoofdstuk 6 worden de resultaten van de vier onderzoeken in breder 
perspectief geplaatst. In 2015 stelde de Institute of Medicine een nieuwe definitie 
voor CVS voor. Deze nieuwe definitie wordt bediscussieerd en aanbevelingen 
voor toekomstig onderzoek worden gedaan.
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